

Malawi Country Operational Plan FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Summary of Planned Funding by Agency and Funding Source							
	Funding Source					Total All	
						Funding	
				Funding	Applied	Sources and	
Agency	GAP	GHP-State	GHP-USAID	Source Total	Pipeline	Applied	
						Pipeline	
						Amount	
State		0		0	462,695	462,695	
USAID		27,765,622	14,950,001	42,715,623	5,383,131	48,098,754	
DOD		1,800,000		1,800,000	500,000	2,300,000	
PC		687,872		687,872	979,999	1,667,871	
HHS/CDC	1,512,500	39,408,180		40,920,680	0	40,920,680	
HHS/HRSA		400,000		400,000	0	400,000	
State/AF		1,000,000		1,000,000	150,000	1,150,000	
Total	1,512,500	71,061,674	14,950,001	87,524,175	7,475,825	95,000,000	

Summary of Planned Funding by Budget Code and Agency

				Agency					
Budget Code	State	DOD	HHS/CDC	HHS/HRS A	PC	State/AF	USAID	On Hold Amount	Total
CIRC		155,000	500,000	0			164,107	0	819,107
НВНС		160,000	2,340,527		38,063		3,302,513	0	5,841,103
HKID	0				6,457	0	5,035,499	0	5,041,956
HLAB			1,250,562				402,109	0	1,652,671
HMBL			1,024,471					0	1,024,471
HTXD							12,069	0	12,069
HTXS		840,000	18,575,683	400,000		1,000,000	14,484,718	0	35,300,401
HVCT		125,000	1,394,489				1,500,846	0	3,020,335
HVMS	0	0	3,376,019		502,388		2,760,612	0	6,639,019
HVOP		150,000			140,964		1,799,427	0	2,090,391



	0	1.800.000	40,920,680	400.000	687,872	1,000,000	42,715,623	0	87,524,175
PDTX		100,000	2,260,994	0			4,406,894	0	6,767,888
PDCS			1,584,523				1,553,405	0	3,137,928
OHSS		50,000	1,876,200	0	0		2,498,839	0	4,425,039
мтст		120,000	1,926,153	0			1,050,726	0	3,096,879
HVTB		50,000	2,303,623	0			2,979,847	0	5,333,470
HVSI	0	50,000	2,507,436	0			764,012	0	3,321,448



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	5,469,664	0
HKID	4,911,274	0
HVTB	5,105,366	0
PDCS	2,975,340	0
Total Technical Area Planned Funding:	18,461,644	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,473,512	0
HVSI	1,954,212	0
OHSS	4,054,477	0
Total Technical Area Planned	7 492 204	
Funding:	7,482,201	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	755,000	0
HMBL	1,000,000	0
HVCT	2,851,888	0
HVOP	1,970,600	0
МТСТ	2,930,299	0
Total Technical Area Planned Funding:	9,507,787	0



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	34,667,333	0
PDTX	6,624,474	0
Total Technical Area Planned Funding:	41,291,807	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	490,460
	Number of new ANC and L&D clients	522,693
	By: Known positives at entry	31,880
	By: Number of new positives identified	27,217
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	59,097
	Required only for DREAMS Countries - By Number of new positives: <15	23
	Required only for DREAMS Countries - By Number of new positives: 15-19	5,736
	Required only for DREAMS Countries - By Number of new positives: 20-24	9,089
	Required only for DREAMS Countries - By Number of known positives: <15	6,734
	Required only for DREAMS Countries - By Number of known	40



posit	tives: 15-19	
Requ	uired only for DREAMS	
Cou	ntries - By Number of known	10,683
posit	tives: 20-24	
Req	uired only for DREAMS	1,477
Cou	ntries - Denominator: <15	1,477
Req	uired only for DREAMS	110 250
Cou	ntries - Denominator: <15-19	110,259
Req	uired only for DREAMS	474.005
Cou	ntries - Denominator: 20-24	174,925
Req	uired only for DREAMS	474 000
Cou	ntries - Denominator: 25-49	174,896
Requ	uired only for DREAMS	00.115
Cou	ntries - Denominator: 50+	60,449
Requ	uired only for DREAMS	
· ·	ntries - By Number of known	10,724
posit	tives: 25-49	
Req	uired only for DREAMS	
Cou	ntries - By Number of known	3,699
posit	tives: 50+	
Req	uired only for DREAMS	
Cou	ntries - By Number of new	9,168
posit	tives: 25-49	
Req	uired only for DREAMS	
Cou	ntries - By Number of new	3,139
posit	tives: 50+	
Ву А	Age (DREAMS SNUs ONLY):	4 005
<15		1,385
Ву А	Age (DREAMS SNUs ONLY):	400 400
15-1	9	103,463
Ву А	Age (DREAMS SNUs ONLY):	404.440
20-2	24	164,146
Ву А	Age (DREAMS SNUs ONLY):	404.404
25-4		164,134



	By Age (DREAMS SNUs ONLY):	56,715
	50+	
	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	n/a
	(MTCT) during pregnancy	
DIATOT ADT DOD	Number of HIV-positive pregnant women who	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	490,460
	New on ART	26,404
	Already on ART at beginning of current pregnancy	29,217
	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	109,348
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	27,102
	By Age: 15-19	43,754
VMMC_CIRC_DSD	By Age: 20-24	21,795
	By Age: 25-29	11,051
	By Age: 30-49	3,586
	By Age: 50+	2,061
	Sum of age disaggregates (Prior to FY15)	94,712
	Sum of age disaggregates (FY15-Current)	109,349
	By HIV status: Number of	



	HIV-positive clients (tested HIV	
	positive at VMMC site)	
	By HIV status: Number of	
	HIV-negative clients (tested HIV	
	negative at VMMC program)	
	By HIV status: Number of clients	
	with undocumented/indeterminate	
	HIV status or not tested for HIV at	
	site	
	By circumcision technique: Surgical VMMC	112,499
	By circumcision technique: Device-based VMMC	3,684
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	290,737
	Total number of people in the	6,438,976



target population	
Age/sex: 10-14 Male	
Age/sex: 15-19 Male	
Age/sex: 20-24 Male	
Age/sex: 25-49 Male	
Age/sex: 50+ Male	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Denominator: Age/sex: 10-14 Male	
Denominator: Age/sex: 15-19 Male	
Denominator: Age/sex: 20-24 Male	
Denominator: Age/sex: 25-49 Male	
Denominator: Age/sex: 50+ Male	
Denominator: Age/sex: 10-14	
Female	
Denominator: Age/sex: 15-19	
Female	
Denominator: Age/sex: 20-24	
Female	
Denominator: Age/sex: 25-49	
Female	
Denominator: Age/sex: 50+ Female	
Service: PP known positive	
Service: PP tested or referred for	
testing as part of program	
New Client: New beneficiary	
New Client: Returning Beneficiary	4.001
Aggregated Age/sex: <15 Male	1,964
Aggregated Age/sex: 15+ Male	138,829



	Aggregated Age/sex: <15 Female	1,706
	Aggregated Age/sex: 15+ Female	148,238
	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,000
	Total number of people in the target population	37,500
	Age/sex: 10-14 Male	
PP_PREV_TA	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	270
	Aggregated Age/sex: 15+ Male	1,530
	Aggregated Age/sex: <15 Female	630
	Aggregated Age/sex: 15+ Female	3,441
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV	n/a
	preventive interventions that are	



based on evidence and/or meet the	
minimum standards required (DSD)	
Number of key populations reached	
with individual and/or small group	
level HIV preventive interventions	40.444
that are based on evidence and/or	10,141
meet the minimum standards	
required	
Total estimated number of key	
population in the catchment area	44,131
By key population type: Men who	
have sex with men who are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	1,245
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	0.040
individual and/or small group level	3,049
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
·	



workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	
Number of key populations reached	
with individual and/or small group	5.047
level HIV preventive interventions	5,847
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs (Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
 in a series and and and	



based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	5,441
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	13,322
estimated number of key	·
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
,	
By key population type: Transgender who are NOT sex	
_	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Female	
sex workers (FSW) (Denominator:	25,368
Total estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs (Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	



	T T		
	By key population type: People in		
	prisons and enclosed settings		
	(Denominator: Total estimated		
	number of key population in the		
catchment area)			
	By Service: KP known status		
	By Service: KP was tested as part		
	of the program and/or KP was		
	referred for testing as part of the		
	program		
	By New Client Status: New		
	beneficiary		
	By New Client Status: REturniong		
	beneficiary within the current report		
	period		
	Number of individuals who received		
	T&C services for HIV and received	3,248,320	
	their test results during the past 12		
	months		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male	196,943	
	Age/sex: 15-19 Male	164,037	
	Age/sex: 20-24 Male	154,373	
	Age/sex: 25-49 Male	437,682	
HTC_TST_DSD	Age/sex: 50+ Male	122,772	
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female	201,567	
	Age/sex: 15-19 Female	194,362	
	Age/sex: 20-24 Female	172,753	
	Age/sex: 25-49 Female	411,702	
	Age/sex: 50+ Female	142,292	
	Test Result by Age and Sex: Positive: 10-14 Male	3,888	
	Test Result by Age and Sex:	18,206	



Positive: 15-19 Male	
Test Result by Age and Sex: Positive: 20-24 Male	16,816
Test Result by Age and Sex: Positive: 25-49 Male	44,503
Test Result by Age and Sex: Positive: 50+ Male	13,845
Test Result by Age and Sex: Positive: 10-14 Female	3,578
Test Result by Age and Sex: Positive: 15-19 Female	22,088
Test Result by Age and Sex: Positive: 20-24 Female	19,448
Test Result by Age and Sex: Positive: 25-49 Female	48,757
Test Result by Age and Sex: Positive: 50+ Female	16,851
Test Result by Age and Sex: Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex: Negative: 25-49 Male	
Test Result by Age and Sex: Negative: 50+ Male	
Test Result by Age and Sex: Negative: 10-14 Female	
Test Result by Age and Sex: Negative: 15-19 Female	
Test Result by Age and Sex: Negative: 20-24 Female	
Test Result by Age and Sex:	



Negative: 25-49 Female	
Test Result by Age and Sex:	
Negative: 50+ Female	
Aggregated Age/sex - USE WITH	717,845
HQ PERMISSION ONLY: <15 Male	,
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	884,020
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	717,243
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	930,425
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	12,425
Test Result by Aggregated Age and Sex: Positive 15+ Male	94,204
Test Result by Aggregated Age and Sex: Positive <15 Female	12,241
Test Result by Aggregated Age and Sex: Positive 15+ Female	107,788
Test Result by Age: Positive: <1	1,929
Test Result by Age: Positive: 1-9	15,456
Age/sex: <1	115,380
A 5 5 /5 5 1 1 1 0	920,878
Age/sex: 1-9	,



(Community): Index testing	
Service Delivery Point	40.450
(Community): Homebased testing	18,459
Service Delivery Point	05.004
(Community): Mobile testing	95,064
Service Delivery Point	75 704
(Community): Other	75,701
Service Delivery Point (Community)	
by Age: <15 index testing	
Service Delivery Point (Community)	
by Age: 15+ index testing	
Service Delivery Point (Community)	
by Age: <15 homebased testing	
Service Delivery Point (Community)	
by Age: 15+ homebased testing	
Service Delivery Point (Community)	
by Age: <15 mobile testing	
Service Delivery Point (Community)	
by Age: 15+ mobile testing	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Community)	
by Age: <15 other	
Service Delivery Point (Facility):	400 705
Inpatient	196,785
Service Delivery Point (Facility):	1 120
Outpatient	1,130
Service Delivery Point (Facility):	E2E 060
Pediatric	535,868
Service Delivery Point (Facility):	0
Malnutrition facilities	0
Service Delivery Point (Facility):	960 499
Other PITC	860,488
Service Delivery Point (Facility):	563,025



1	
VCT	
Service Delivery Point (Facility): VMMC	27,822
Service Delivery Point (Facility): PMTCT	860,422
Service Delivery Point (Facility): TB Clinics	27,443
Service Delivery Point (Facility): Index testing	0
Service Delivery Point (Facility) by Age: <15 Inpatient	
Service Delivery Point (Facility) by Age: >15 Inpatient	
Service Delivery Point (Facility) by Age: <15 Outpatient	
Service Delivery Point (Facility) by Age: >15 Outpatient	
Service Delivery Point (Facility) by Age: <15 Pediatroc	
Service Delivery Point (Facility) by Age: >15 Pediatroc	
Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
Service Delivery Point (Facility) by Age: <15 Other PITC	
Service Delivery Point (Facility) by Age: >15 Other PITC	l
Service Delivery Point (Facility) by Age: <15 VCT	
Service Delivery Point (Facility) by Age: >15 VCT	
Service Delivery Point (Facility) by	



	Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	22,217
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	24,292
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 20-24	
	·



(Numerator: Number of registered new and relapsed TB cases with	
documented HIV status, during the reporting period)	
Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	492
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,395
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	904
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13,426
Result: Known HIV positive at service entry	



Result: New HIV positive Result: HIV Negative Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)		
Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	Result: New HIV positive	
number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	Result: HIV Negative	
relapsed TB cases, during the reporting period.) Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	Age/Sex: <1 (Denominator: Total	
reporting period.) Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting the reporting period.)	number of registered new and	
Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	relapsed TB cases, during the	
number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	reporting period.)	
relapsed TB cases, during the reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	Age/Sex: 1-9 (Denominator: Total	
reporting period.) Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	number of registered new and	
Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	relapsed TB cases, during the	
(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	reporting period.)	
registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	Age/Sex: Male 10-14	
cases, during the reporting period.) Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	(Denominator: Total number of	
Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	registered new and relapsed TB	
(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	cases, during the reporting period.)	
registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	Age/Sex: Male 15-19	
cases, during the reporting period.) Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	(Denominator: Total number of	
Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	registered new and relapsed TB	
(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	cases, during the reporting period.)	
registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	Age/Sex: Male 20-24	
cases, during the reporting period.) Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	(Denominator: Total number of	
Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	registered new and relapsed TB	
(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	cases, during the reporting period.)	
registered new and relapsed TB cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	Age/Sex: Male 25-49	
cases, during the reporting period.) Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	(Denominator: Total number of	
Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the	registered new and relapsed TB	
Total number of registered new and relapsed TB cases, during the	cases, during the reporting period.)	
relapsed TB cases, during the	Age/Sex: Male 50+ (Denominator:	
	Total number of registered new and	
reporting period.)	relapsed TB cases, during the	
	reporting period.)	
Age/Sex: Female 10-14	Age/Sex: Female 10-14	
(Denominator: Total number of	(Denominator: Total number of	
registered new and relapsed TB	registered new and relapsed TB	
cases, during the reporting period.)	cases, during the reporting period.)	
Age/Sex: Female 15-19	Age/Sex: Female 15-19	



	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Age/Sex: Female 50+	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Aggregated Age/Sex: Female <15	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period)	
	Number of people receiving	7,891
OFNE ORY DOS	post-GBV care	1,091
GEND_GBV_DSD	Age/Sex: <10 Male	0
	Age/Sex: 10-14 Male	0



	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	134
	Age/Sex: 25-49 Male	106
	Age/Sex: 50+ Male	0
	Age/Sex: <10 Female	0
	Age/Sex: 10-14 Female	1,657
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	3,929
	Age/Sex: 25-49 Female	673
	Age/Sex: 50+ Female	0
	Sum of Age/Sex Disaggregates	1,657
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
	By type of service: Sexual Violence (Post-Rape Care)	7,891
	By PEP service provision (related to sexual violence services provided)	0
	Age/Sex: 15-19 Female	1,354
	Age/Sex: 15-19 male	43
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	129,249
OVC_SERV_DSD	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	29,718
	Age/Sex: 10-14 Female	



Age/Sex: 15-17 Female	
By: Age/sex: 18-24 Female	
By: Age/sex: 25+ Female	
Age/Sex: 18+ Female	31,657
Sum of Age/Sex disaggregates	61,375
Required only for DREAMS	
countries - By service, age and	0
sex: Education Support Female <1	
Required only for DREAMS	
countries - By service, age and	5
sex: Education Support Female	3
10-14	
Required only for DREAMS	
countries - By service, age and	0
sex: Education Support Female	- -
15-17	
Required only for DREAMS	
countries - By service, age and	0
sex: Education Support Female	
18-24	
Required only for DREAMS	
countries - By service, age and	0
sex: Education Support Female	
25+	
Required only for DREAMS	
countries - By service, age and	0
sex: Education Support Male <1	
Required only for DREAMS	
countries - By service, age and	0
sex: Education Support Male 10-14	
Required only for DREAMS	0
countries - By service, age and	0
sex: Education Support Male 15-17	
Required only for DREAMS	0
countries - By service, age and	



sex: Education Support Male 18-24	
Required only for DREAMS	
countries - By service, age and	0
sex: Education Support Male 25+	
Required only for DREAMS	
countries - By service, age and	4.540
sex: Parenting/Caregiver Programs	1,542
Female <1	
Required only for DREAMS	
countries - By service, age and	_
sex: Parenting/Caregiver Programs	0
Female 10-14	
Required only for DREAMS	
countries - By service, age and	_
sex: Parenting/Caregiver Programs	0
Female 15-17	
Required only for DREAMS	
countries - By service, age and	•
sex: Parenting/Caregiver Programs	0
Female 18-24	
Required only for DREAMS	
countries - By service, age and	0
sex: Parenting/Caregiver Programs	0
Female 25+	
Required only for DREAMS	
countries - By service, age and	4 44 4
sex: Parenting/Caregiver Programs	1,414
Male <1	
Required only for DREAMS	
countries - By service, age and	0
sex: Parenting/Caregiver Programs	0
Male 10-14	
Required only for DREAMS	
countries - By service, age and	0
sex: Parenting/Caregiver Programs	



Male 15-17	
Required only for DREAMS	
countries - By service, age and	0
sex: Parenting/Caregiver Programs	
Male 18-24	
Required only for DREAMS	
countries - By service, age and	0
sex: Parenting/Caregiver Programs	
Male 25+	
Required only for DREAMS	
countries - By service, age and	0
sex: Social Protection Female <1	
Required only for DREAMS	
countries - By service, age and	0
sex: Social Protection Female	0
10-14	
Required only for DREAMS	
countries - By service, age and	_
sex: Social Protection Female	0
15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Female	0
18-24	
Required only for DREAMS	
countries - By service, age and	0
sex: Social Protection Female 25+	-
Required only for DREAMS	
countries - By service, age and	0
sex: Social Protection Male <1	· ·
Required only for DREAMS	0
countries - By service, age and	0
sex: Social Protection Male 10-14	
Required only for DREAMS	0
countries - By service, age and	-



se	ex: Social Protection Male 15-17	
R	Required only for DREAMS	
cc	ountries - By service, age and	0
se	ex: Social Protection Male 18-24	
R	Required only for DREAMS	
cc	ountries - By service, age and	0
Se	ex: Social Protection Male 25+	
R	lequired only for DREAMS	
	ountries - By service, age and	
	ex: Economic Strengthening	0
F	emale <1	
R	lequired only for DREAMS	
	ountries - By service, age and	_
	ex: Economic Strengthening	0
F	emale 10-14	
R	lequired only for DREAMS	
	ountries - By service, age and	
	ex: Economic Strengthening	3
F	emale 15-17	
R	lequired only for DREAMS	
cc	ountries - By service, age and	
SE	ex: Economic Strengthening	4,544
F	emale 18-24	
R	Required only for DREAMS	
cc	ountries - By service, age and	
SE	ex: Economic Strengthening	18,260
	emale 25+	
R	lequired only for DREAMS	
	ountries - By service, age and	•
se	ex: Economic Strengthening Male	0
<		
R	lequired only for DREAMS	
	ountries - By service, age and	
	ex: Economic Strengthening Male	0
	0-14	



<u> </u>		
c s	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male	0
c s	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male	1,162
c s	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	3,477
С	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	22
С	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	89
С	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	27
С	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	2,730
С	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	10,519
С	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	12
С	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	229
	Required only for DREAMS countries - By service, age and	61



sex: Other Services Male 15-17	
Required only for DREAMS	
countries - By service, age and	885
sex: Other Services Male 18-24	
Required only for DREAMS	
countries - By service, age and	2,196
sex: Other Services Male 25+	
Age/Sex: <1	
Age/Sex: 1-9	
Required only for DREAMS	
countries - By service, age and	28,688
sex: Education Support 1-9 Male	
Required only for DREAMS	
countries - By service, age and	7 247
sex: Parenting/Caregiver Programs	7,217
Male 1-9	
Required only for DREAMS	
countries - By service, age and	0
sex: Social Protection Programs	U
Male 1-9	
Required only for DREAMS	
countries - By service, age and	531
sex: Economic Strengthening Male	551
1-9	
Required only for DREAMS	
countries - By service, age and	959
sex: Other Services Male 1-9	
Program Completion: Active	
Program Completion: Graduation	
Program Completion: Transferred	
Program Completion: Exited	
without graduation	
By Aggregated Age/Sex: <18 Male	33,248
By Aggregated Age/Sex: 18+ Male	



	By Aggregated Age/Sex: <18 Female	34,626
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	36,633
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	10,263
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	2,619
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	685
	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	9,464
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	10,413



period	
Age/Sex: >1 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: 1-9 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	



the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	



	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Male <15	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	202
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Male 15+	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	3,078
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Female <15	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	377
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Numerator: The number of	
	registered new and relapse TB	
	cases with documented	5,818
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The	
	•	



number of registered new and
relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: 1-9 (Denominator: The
number of registered new and
relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 10-14
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 15-19
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
,
Age/Sex: Male 20-24
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 25-49
Age/Sex. Male 25-43
(Denominator: The number of
-



T
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 50+ (Denominator:
The number of registered new and
relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 10-14
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 15-19
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 20-24
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 25-49
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting



period)
Age/Sex: Female 50+
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Aggregated Age/Sex: Male <15
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Aggregated Age/Sex: Male 15+
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Aggregated Age/Sex: Female <15
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting period)
,
Aggregated Age/Sex: Female 15+
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)



	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	637,534
	Screened for TB by Age/Sex:<15	14,600
	Screened for TB by Age/Sex: 15+ Male	213,047
	Screened for TB by Age/Sex:<15 Female	26,235
	Screened for TB by Age/Sex: 15+ Female	383,652
	Screen Result: Screened Positive for TB	6,303
TR CORENDY DOD	TB Positive by Age/Sex: <15 Male	
TB_SCREENDX_DSD	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15	
	Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	460,948
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	377,080
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	42,247
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	41,621
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a



Number of infants who had a	
virologic HIV test within 12 months	
of birth during the reporting period	
Number of HIV- positive pregnant	
women identified during the	
reporting period (include known	
HIV-positive women at entry into	
PMTCT)	
By infants who received a virologic	14.000
test within 2 months of birth	14,909
By infants who received their first	
virologic HIV test between 2 and 12	25,999
months of age	
Sum of Infant Age disaggregates	40,908
By infants with a positive virologic	
test result within 12 months of birth	
Number of infants with a positive	
virological test result within 2	416
months of birth	
Number of infants with a negative	
virological test result within 2	
months of birth	
Number of infants with a positive	
virological test result between 2	
and 12 months of birth	
Number of infants with a negative	
virological test result between 2	
and 12 months of birth	
Number of infants with a positive	
virological test result within 12	747
months of birth	
Number of adults and children	
receiving antiretroviral therapy	671,100
(ART)	
_ I	
	virologic HIV test within 12 months of birth during the reporting period Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) By infants who received a virologic test within 2 months of birth By infants who received their first virologic HIV test between 2 and 12 months of age Sum of Infant Age disaggregates By infants with a positive virologic test result within 12 months of birth Number of infants with a positive virological test result within 2 months of birth Number of infants with a negative virological test result within 2 months of birth Number of infants with a negative virological test result between 2 and 12 months of birth Number of infants with a negative virological test result between 2 and 12 months of birth Number of infants with a positive virological test result between 2 and 12 months of birth Number of infants with a positive virological test result within 12 months of birth Number of infants with a positive virological test result within 12 months of birth Number of infants with a positive virological test result within 12 months of birth Number of adults and children receiving antiretroviral therapy



	A 72/Cay 45 40 Famala	24.005
	Age/Sex: 15-19 Female	21,885
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	35,669
	Aggregated Age/Sex: 15+ Male	219,532
	Aggregated Age/Sex: <15 Female	37,855
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	378,043
	Sum of Aggregated Age/Sex <15	73,524
	Sum of Aggregated Age/Sex 15+	597,575
	Sum of Aggregated Age/Sex disaggregates	671,099
	Age/Sex: <1	9,971
	Age/Sex: <1-9	43,690
	Age/Sex: 10-14 Male	9,154
	Age/Sex: 10-14 Female	10,034
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	7,777
	Age/Sex: 25-49 Male	159,911
	Age/Sex: 50+ Male	28,812
	Age/Sex: 20-24 Female	68,814
	Age/Sex: 25-49 Female	276,922
	Age/Sex: 50+ Female	22,113
	Number of adults and children	
	newly enrolled on antiretroviral	161,249
	therapy (ART)	
X_NEW_DSD	By Age/Sex: <1	2,281
	By Age/Sex: 1-9	10,014
	By Age/Sex: 10-14 Male	2,093



By Age/Sex: 15-19 Male	1,093
By Age/Sex: 20-24 Male	1,842
By Age/Sex: 25-49 Male	41,313
By Age/Sex: 50+ Male	6,806
By Age/Sex: 10-14 Female	2,304
By Age/Sex: 15-19 Female	5,166
By Age/Sex: 20-24 Female	16,220
By Age/Sex: 25-49 Female	65,366
By Age/Sex: 50+ Female	5,227
Sum of Age/Sex disaggregates	147,430
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male	
Aggregated Grouping by Age/Sex: <15 Male	8,190
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	51,680
Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	8,696
Aggregated Grouping by Age/Sex: 15+ Female	92,683
Sum of Aggregated Age/Sex disaggregates	161,249
Pregnancy status	
Breastfeeding status	
Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD Percentage of ART patients with a viral load result	n/a



documented in the medical record	
and/or laboratory information	
systems (LIS) within the past 12	
months with a suppressed viral	
load (<1000 copies/ml)	
Number of adults and pediatric	
patients on ART with suppressed	
viral load results (<1,000 copies/ml)	200.074
documented in the medical records	209,074
and /or supporting laboratory	
results within the past 12 months.	
Number of adult and pediatric ART	
patients with a viral load result	
documented in the patient medical	232,309
record and /or laboratory records	
in the past 12 months.	
Numerator: Indication: Routine	188,173
Numerator: Indication: Targeted	90
Numerator: Preg/BF by Indication:	
Pregnant Routine	
Numerator: Preg/BF by Indication:	
Breastfeeding Routine	
Numerator: Preg/BF by Indication:	
Pregnant Targeted	
Numerator: Preg/BF by Indication:	
Breastfeeding Targeted	
Numerator: Age/Sex by Indication:	
<1 Routine	
Numerator: Age/Sex by Indication:	
1-9 Routine	
Numerator: Age/Sex by Indication:	
10-14 Male Routine	
Numerator: Age/Sex by Indication:	
15-19 Male Routine	
Numerator: Age/Sex by Indication:	



20-24 Male Routine	
Numerator: Age/Sex by Indication: 25-49 Male Routine	
Numerator: Age/Sex by Indication: 50+ Male Routine	
Numerator: Age/Sex by Indication: 10-14 Female Routine	
Numerator: Age/Sex by Indication: 15-19 Female Routine	
Numerator: Age/Sex by Indication: 20-24 Female Routine	
Numerator: Age/Sex by Indication: 25-49 Female Routine	
Numerator: Age/Sex by Indication: 50+ Female Routine	
Numerator: Age/Sex by Indication: <1 Targeted	
Numerator: Age/Sex by Indication: 1-9 Targeted	
Numerator: Age/Sex by Indication: 10-14 Male Targeted	
Numerator: Age/Sex by Indication: 15-19 Male Targeted	
Numerator: Age/Sex by Indication: 20-24 Male Targeted	
Numerator: Age/Sex by Indication: 25-49 Male Targeted	
Numerator: Age/Sex by Indication: 50+ Male Targeted	
Numerator: Age/Sex by Indication: 10-14 Female Targeted	
Numerator: Age/Sex by Indication: 15-19 Female Targeted	
Numerator: Age/Sex by Indication:	



20-24 Female Targeted Numerator: Age/Sex by Indication: 25-49 Female Targeted Numerator: Age/Sex by Indication: 50+ Female Targeted	
25-49 Female Targeted Numerator: Age/Sex by Indication:	
Numerator: Age/Sex by Indication:	
50+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by	
Indication: <15 Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Routine	
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Routine	
No constant A constant A con /C con less	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	
Indication: 15+ Female Routine	
Indication: 15+ Female Routine Denominator: Indication: Routine 209,074	
Indication: 15+ Female Routine Denominator: Indication: Routine 209,074 Denominator: Indication: Targeted 103	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by Indication: Pregnant Routine	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by Indication: Breastfeeding Routine	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by Indication: Breastfeeding Routine Denominator: Preg/BF by	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by Indication: Breastfeeding Routine Denominator: Preg/BF by Indication: Pregnant Targeted	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by Indication: Breastfeeding Routine Denominator: Preg/BF by Indication: Pregnant Targeted Denominator: Preg/BF by Indication: Pregnant Targeted	
Indication: 15+ Female Routine Denominator: Indication: Routine Denominator: Indication: Targeted Denominator: Preg/BF by Indication: Pregnant Routine Denominator: Preg/BF by Indication: Breastfeeding Routine Denominator: Preg/BF by Indication: Pregnant Targeted Denominator: Preg/BF by Indication: Pregnant Targeted	



Indication: 1-9 Routine
Denominator: Age/Sex by
Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: <1 Targeted
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by



Indication: 50+ Male Targeted	
Denominator: Age/Sex by	
Indication: 10-14 Female Targeted	
Denominator: Age/Sex by	
Indication: 15-19 Female Targeted	
Denominator: Age/Sex by	
Indication: 20-24 Female Targeted	
Denominator: Age/Sex by	
Indication: 25-49 Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Routine	
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Routine	
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Routine	
Numerator Aggregated Age/Sex:	9,134
<15 Male	3,134
Numerator Aggregated Age/Sex:	67,913
15+ Male	07,910
Numerator Aggregated Age/Sex:	9,694
<15 Female	0,007
Numerator Aggregated Age/Sex:	122,333



	15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	10,147
	Denominator Aggregated Age/Sex: 15+ Male	75,463
	Denominator Aggregated Age/Sex: <15 Female	10,766
	Denominator Aggregated Age/Sex: 15+ Female	135,933
TX_RET_D\$D	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	119,146
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	131,431
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,271
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,597
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,178



Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	838
Age/Sed: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,389
Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	31,368
Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,162
Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,284
Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,914
Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,330
Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	49,637



Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,959
Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,413
Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,180
Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,293
Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	937
Age/Sex: 20-24 Male (Denominator: Total number of	1,530





those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	40.000
beginning of the reporting period,	13,603
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	- 4.000
beginning of the reporting period,	54,686
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	4.000
beginning of the reporting period,	4,382
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	



adult	s and children who initiated	
ART	in the 12 months prior to the	
begin	nning of the reporting period,	
includ	ding those who have died,	
those	e who have stopped ART, and	
those	e lost to follow-up)	
Aggre	egated Age: 15+	
(Den	ominator: Total number of	
adult	s and children who initiated	
ART	in the 12 months prior to the	
begin	nning of the reporting period,	
includ	ding those who have died,	
those	e who have stopped ART, and	
those	e lost to follow-up)	
Num	erator by Status: Pregnant	
Num	erator by Status:	
Breas	stfeeding	
Deno	ominator by Status: Pregnant	
Deno	ominator by Status:	
Breas	stfeeding	
Aggre	egated Age/Sex: <15 Male	
	nerator: Number of adults and	
`	ren who are still alive and on	4,537
	ment at 12 months after	,
	ting ART)	
	egated Age/Sex: 15+ Male	
	nerator: Number of adults and	
`	ren who are still alive and on	38,718
	ment at 12 months after	50,710
	ting ART)	
	egated Age/Sex: <15 Female	
`	nerator: Number of adults and	4.0.1
	ren who are still alive and on	4,811
	ment at 12 months after	
nitiat	ting ART)	



Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and	
children who are still alive and on	71,079
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	5,014
beginning of the reporting period,	5,014
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	40.704
beginning of the reporting period,	42,791
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: <15 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	5,321
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age/Sex: 15+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	78,490
beginning of the reporting period,	. 5, 100
including those who have died,	
those who have stopped ART, and	
and the nave stopped Arti, and	



	those lost to follow-up)	
	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	57
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	57
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	57
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	57
	CD4: Number of laboratories that participate in this PT program	57
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	57
	Early infant diagnostics: Number of laboratories that perform this testing	9
	Early infant diagnostics: Number of laboratories that participate in this PT program	9
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	HIV viral load: Number of	9



laboratories that perform this testing HIV viral load: Number of laboratories that participate in this PT program HIV viral load: Number of laboratories that achieve 9
HIV viral load: Number of laboratories that participate in this 9 PT program HIV viral load: Number of laboratories that achieve
laboratories that participate in this 9 PT program HIV viral load: Number of laboratories that achieve
PT program HIV viral load: Number of laboratories that achieve
HIV viral load: Number of laboratories that achieve
laboratories that achieve
9
and the suppose of the section
acceptable successful passing
criteria in this PT program
TB diagnostics (AFB microscopy):
Number of laboratories that 57
perform this testing
TB diagnostics (AFB microscopy):
Number of laboratories that 57
participate in this PT program
TB diagnostics (AFB microscopy):
Number of laboratories that
achieve acceptable successful
passing criteria in this PT program
TB diagnostics (Xpert MTB/RIF):
Number of laboratories that 44
perform this testing
TB diagnostics (Xpert MTB/RIF):
Number of laboratories that 44
participate in this PT program
TB diagnostics (Xpert MTB/RIF):
Number of laboratories that
achieve acceptable successful
passing criteria in this PT program
TB diagnostics (Culture/DST):
Number of laboratories that 2
perform this testing
TB diagnostics (Culture/DST):
Number of laboratories that 2
participate in this PT program



	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	284
	By Graduates: Doctors	4
HRH_PRE	By Graduates: Nurses	230
	By Graduates: Midwives	
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	50
	Sum of Graduates disaggreagtes	284



Partners and Implementing Mechanisms

Partner List

Partner	Liot				
Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9281	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services	GHP-State	0
			Administration	1	
9883	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
10427	Malawi Blood Transfusion Service	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
11453	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	148,031
12111	Ministry of Health, Malawi	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
12116	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of	GHP-State	0



			African Affairs		
12119	Global AIDS Interfaith Alliance	FBO	U.S. Agency for International Development	GHP-State	0
12131	Christian Health Association of Malawi	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,120,000
14113	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,400,000
14242	FHI 360	NGO	U.S. Agency for International Development	GHP-State	350,000
14432	JHPIEGO	University	U.S. Department of Defense	GHP-State	0
14441	Lighthouse	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,700,000
14442	BAOBAB Health Partnership	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	2,750,000



			Prevention		
15888	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-USAID	1,200,000
16486	Save The Children Federation Inc	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	0
16678	Management Sciences for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,752,376
16704	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-State	4,800,000
16716	Counterpart International	NGO	U.S. Agency for International Development	GHP-State	832,110
16794	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
17097	Project Concern International	NGO	U.S. Department of Defense	GHP-State	1,580,000
17268	Columbia University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
17341	University	Private Contractor	U.S. Department	GHP-State	4,200,000



	Research		of Health and		
	Corporation, LLC		Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
17451	Universtiy of	Implementing	Services/Centers	GHP-State	4,900,000
	Washington	Agency	for Disease		
			Control and		
			Prevention		
			U.S. Agency for		
17480	Futures Group	Private Contractor		GHP-USAID	300,000
	·		Development		,
			U.S. Department		
			of Health and		
	National	Host Country	Human		
17487	Registration	Government	Services/Centers	GHP-State	400,000
	Bureau Malawi	Agency	for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	University of		Human		
17488	Malawi College of	University	Services/Centers	GHP-State	1,000,000
	Medicine		for Disease		
			Control and		
			Prevention		
			U.S. Agency for		
17585	FHI 360	NGO	International	GHP-State	1,773,759
			Development		
	Donulation		U.S. Agency for		
17590	Population	NGO	International	GHP-State	400,000
	Council		Development		



	Population		U.S. Agency for		
17594	Services	NGO	International	GHP-State	0
	International		Development		
17720	VISTA	Implementing	U.S. Department	GHP-State	0
17720	PARTNERS	Agency	of Defense	OTIT Otate	Ů
	KNCV		U.S. Agency for		
18005	Tuberculosis	NGO	International	GHP-USAID	350,000
	Foundation		Development		
18024	TBD	TBD	Redacted	Redacted	Redacted
18025	TBD	TBD	Redacted	Redacted	Redacted
18028	World Learning	NGO	U.S. Agency for International Development	GHP-USAID	847,000
18045	JHPIEGO	University	U.S. Department of Defense	GHP-State	70,000
18063	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	1,680,000
18125	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	600,000
18142	Population Services International	NGO	U.S. Agency for International Development	GHP-USAID	998,000
18234	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	20,724,217
18244	TBD	TBD	Redacted	Redacted	Redacted
18245	TBD	TBD	Redacted	Redacted	Redacted
18246	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services	GHP-State	400,000



			Administration		
18247	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
18256	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	1,000,000
18279	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	1,709,642
18303	TBD	TBD	Redacted	Redacted	Redacted
18305	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	1,230,000
18351	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

implementing meenanism betans		
Mechanism ID: 9281	Mechanism Name: I-TECH	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 9883	Mechanism Name: Prevention for Populations and Settings with High Risk Behaviors	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	0

(No data provided.)

Budget Code Information

Budget Code Information			
Mechanism ID:	9883		
Mechanism Name:	Prevention for Populations and Settings with High Risk Behaviors		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 10427	Mechanism Name: Supporting the Safe, Adequate and Reliable Supply of Blood and Blood Products through the Malawi Blood Transfusion Service and its Support to Hospitals throughout Malawi, under the PEPFAR and the
	Global Health Initiative
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Malawi Blood Transfusion Sel	rvice
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 1,000,000
Funding Source	Funding Amount
GHP-State	1,000,000

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	Products through the Malawi Blood Transfusion Service and its Support to Hospitals throughout Malawi, under the PEPFAR and the Global Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	1,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 11453	Mechanism Name: Peace Corps Volunteers
Funding Agency: PC Procurement Type: USG Core	
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:	
Total All Funding Sources: 148,031		
Applied Pipeline Amount: 70,000		
Total All Funding Sources and Applied Pipeline Amount: 218,031		
Funding Source	Funding Amount	
GHP-State	148,031	

Gender: Gender Equality	57,636
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	l1453		
Mechanism Name:	Peace Corps Volunteers		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HBHC 23,211 0		
Strategic Area	Budget Code Planned Amount On Hold Amount		



Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	124,820	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,000
PP_PREV_TA	Total number of people in the target population	37,500
PP_PREV_TA	Aggregated Age/sex: <15 Male	270
PP_PREV_TA	Aggregated Age/sex: 15+ Male	1,530
PP_PREV_TA	Aggregated Age/sex: <15 Female	630
PP_PREV_TA	Aggregated Age/sex: 15+ Female	3,570

Mechanism ID: 12111	Mechanism Name: Supporting implementation of National AIDS Framework through improving coverage and quality of HIV and AIDS Services
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Ma	lawi
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 250,000
Funding Source	Funding Amount
GHP-State	250,000



(No data provided.)

Mechanism ID: Mechanism Name:	improving coverage and quality of HIV and AIDS Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	88,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	6,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	110,650	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12116	Mechanism Name: ASGF/State for Ambassadors Small Grant for HIV/AIDS
Funding Agency: State/AF	Procurement Type: Cooperative Agreement



Prime Partner Name: U.S. Department of State		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0		
Applied Pipeline Amount: 150,000		
Total All Funding Sources and Applied Pipeline Amount: 150,000		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

Budget Code Information

-uaget code imenin			
Mechanism ID:	12116		
Mechanism Name:	ASGF/State for Ambassadors Small Grant for HIV/AIDS		
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

	Mechanism Name: Building the Nursing
Mechanism ID: 12119	Workforce and Nursing Training Capacity in
	Malawi



Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Global AIDS Interfaith Alliance		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

Budget Code Information

Baaget Gode Inform	I		
Mechanism ID: Mechanism Name: Prime Partner Name:	Building the Nursing Workforce and Nursing Training Capacity in Malawi		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Mechanism ID: 12131	Mechanism Name: Strengthening the Delivery, Coordination, and Monitoring of HIV Services in Malawi through a Faith-based Institution under the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,120,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,120,000		
Funding Source	Funding Amount	
GHP-State	1,120,000	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,120,000	
----------------------------	-----------	--

<u> </u>			
	12131		
Mechanism ID:	Strengthening the Delivery, Coordination, and Monitoring of HIV		
Mechanism Name:	: Services in Malawi through a Faith-based Institution under the		
Prime Partner Name: President's Emergency Plan for AIDS Relief (PEPFAR)			
Christian Health Association of Malawi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	575,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	23,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	521,700	0

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	150
HRH_PRE	By Graduates: Nurses	150
HRH_PRE	Sum of Graduates disaggreagtes	150

Implementing Mechanism Details

Mechanism ID: 14113	Mechanism Name: District Health System Strengthening and Quality Improvement for	
	Service Delivery in Malawi under PEPFAR	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 4,400,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 4,400,000		
Funding Source Funding Amount		
GHP-State	4,400,000	



Cross-Cutting Budget Attribution(s)

Human Resources for Health	270,000

Budget Code Information			
Mechanism ID: Mechanism Name: Mechanism Name: Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	331,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	422,360	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	43,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	55,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	60,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	255,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	301,260	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,491,490	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	438,990	0

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,247
PMTCT_ART_DSD	New on ART	3,210
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,482
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	95,247
PMTCT_STAT_DSD	Number of new ANC and L&D clients	100,819
PMTCT_STAT_DSD	By: Known positives at entry	3,823
PMTCT_STAT_DSD	By: Number of new positives identified	3,258
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	7,081
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	689
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	1,090
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	805
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	1,285



	known positives: 20-24	
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	287
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	21,295
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	33,786
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	33,775
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	11,676
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,286
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	444
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	1,101
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	376
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	268
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	20,120
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	31,914
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	31,914
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	11,031
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	474,419
HTC_TST_DSD	Age/sex: 10-14 Male	29,915
HTC_TST_DSD	Age/sex: 15-19 Male	24,694
HTC_TST_DSD	Age/sex: 20-24 Male	20,531
HTC_TST_DSD	Age/sex: 25-49 Male	58,593
HTC_TST_DSD	Age/sex: 50+ Male	18,786
HTC_TST_DSD	Age/sex: 10-14 Female	30,846



HTC_TST_DSD	Age/sex: 15-19 Female	25,796	
HTC_TST_DSD	Age/sex: 20-24 Female 21,6		
HTC_TST_DSD	Age/sex: 25-49 Female	62,597	
HTC_TST_DSD	Age/sex: 50+ Female 21,6		
HTC_TST_DSD	Sum of Age/Sex disaggregates	315,052	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	485	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	1,447	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,207	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	3,429	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1,101	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	500	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,511	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,270	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,668	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1,269	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	110,039	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	122,602	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	110,090	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	131,688	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	220,129	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	254,290	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	474,419	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male		
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	7,183	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	5 1,779	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	7,713	



Female			
HTC_TST_DSD	Test Result by Age: Positive: <1	285	
HTC_TST_DSD	Test Result by Age: Positive: 1-9	2,288	
HTC_TST_DSD	Age/sex: <1	17,743	
HTC_TST_DSD	Age/sex: 1-9	141,624	
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	30,833	
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0	
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	83,969	
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0	
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	134,736	
HTC_TST_DSD	Service Delivery Point (Facility): VCT	85,873	
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0	
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	134,736	
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	4,272	
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0	
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,687	
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,933	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	80	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,229	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	Age/Sex: Female <15 (Numerator: Number stered new and relapsed TB cases with 149	
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)		2,229	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	1,547	



	during TB treatment during the reporting period		
	The number of registered new and relapse TB cases		
TB_ART_DSD	with documented HIV-positive status during TB	1,706	
	treatment during the reporting period		
	Aggregated Age/Sex: Male <15 (Numerator: The		
TB_ART_DSD	number of registered new and relapse TB cases with	35	
16_/\(\(\)\	documented HIV-positive status who are on ART during	00	
	TB treatment during the reporting period)		
	Aggregated Age/Sex: Male 15+ (Numerator: The		
TB_ART_DSD	number of registered new and relapse TB cases with	514	
10_/11(1_000	documented HIV-positive status who are on ART during	014	
	TB treatment during the reporting period)		
	Aggregated Age/Sex: Female <15 (Numerator: The		
TB_ART_DSD	number of registered new and relapse TB cases with	61	
	documented HIV-positive status who are on ART during		
	TB treatment during the reporting period)		
	Aggregated Age/Sex: Female 15+ (Numerator: The		
TB_ART_DSD	number of registered new and relapse TB cases with	937	
• -	documented HIV-positive status who are on ART during		
	TB treatment during the reporting period)		
	The number of PLHIV who were screened for TB		
TB_SCREENDX_DSD	symptoms at the last clinical visit at a HIV facility during	74,422	
	the reporting period.		
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,688	
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	24,794	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	3,058	
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	ed for TB by Age/Sex: 15+ Female 44,882	
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB 7		
TD CODEFNEY DOD	[Sub-Disagg of Screen Result] Specimen Sent:	E4 400	
TB_SCREENDX_DSD	Specimen sent for bacteriologic diagnosis of active TB	54,408	
[Sub-Disagg of Specimen Sent] Diagnostic Test:		44 E00	
TB_SCREENDX_DSD	only	44,509	
TD CODEENING DOD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert	4,987	
TB_SCREENDX_DSD	MTB/RIF assay	4,307	



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	4,912
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,810
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,076
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,886
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	52
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	93
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	78,345
TX_CURR_DSD	Age/Sex: 15-19 Male	550
TX_CURR_DSD	Age/Sex: 15-19 Female	2,582
TX_CURR_DSD	Sum of age/sex disaggregates	3,132
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,930
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	25,543
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,230
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	42,642
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10,160
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	68,185
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	78,345
TX_CURR_DSD	Age/Sex: <1	1,392
TX_CURR_DSD	Age/Sex: <1-9	6,093
TX_CURR_DSD	Age/Sex: 10-14 Male	1,275
TX_CURR_DSD	Age/Sex: 10-14 Female	1,402
TX_CURR_DSD	Age/Sex: 20-24 Male	922
TX_CURR_DSD	Age/Sex: 25-49 Male	17,320
TX_CURR_DSD	Age/Sex: 50+ Male	3,400
TX_CURR_DSD	Age/Sex: 20-24 Female	8,122
TX_CURR_DSD	Age/Sex: 25-49 Female	32,683
TX_CURR_DSD	Age/Sex: 50+ Female	2,604



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)		
TX_NEW_DSD	By Age/Sex: <1	346	
TX_NEW_DSD	By Age/Sex: 1-9	1,508	
TX_NEW_DSD	By Age/Sex: 10-14 Male	316	
TX_NEW_DSD	By Age/Sex: 15-19 Male	89	
TX_NEW_DSD	By Age/Sex: 20-24 Male	153	
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,532	
TX_NEW_DSD	By Age/Sex: 50+ Male	580	
TX_NEW_DSD	By Age/Sex: 10-14 Female	348	
TX_NEW_DSD	By Age/Sex: 15-19 Female	446	
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,387	
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,600	
TX_NEW_DSD	By Age/Sex: 50+ Female	448	
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,899	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,223	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,369	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,295	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,866	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	14,753	
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	24,679	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	ord 27,417	
TX_PVLS_DSD	Numerator: Indication: Routine	22,210	
TX_PVLS_DSD	Numerator: Indication: Targeted	7	
TX_PVLS_DSD	Denominator: Indication: Routine	24,679	
TX_PVLS_DSD	Denominator: Indication: Targeted	8	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,078	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	8,016	



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,143	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	14,442	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,197	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	8,907	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,271	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	16,042	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,921	
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	147	
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	644	
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	136	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	95	
TX_RET_DSD	Age/Sed: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	163	
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,606	
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	593	
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults	147	



and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including		,	
Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months			
TX_RET_DSD and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		months after initiating ART	
months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		Age/Sex: 15-19 Female (Numerator: Number of adults	
Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 5,725 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	TX_RET_DSD	and children who are still alive and on treatment at 12	444
TX_RET_DSD and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 5,725 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		months after initiating ART	
months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 5,725 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		Age/Sex: 20-24 Female (Numerator: Number of adults	
Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	TX_RET_DSD	and children who are still alive and on treatment at 12	1,416
TX_RET_DSD and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		months after initiating ART	
months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		Age/Sex: 25-49 Female (Numerator: Number of adults	
Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	TX_RET_DSD	and children who are still alive and on treatment at 12	5,725
TX_RET_DSD and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		months after initiating ART	
months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		Age/Sex: 50+ Female (Numerator: Number of adults	
Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	TX_RET_DSD	and children who are still alive and on treatment at 12	451
children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		months after initiating ART	
TX_RET_DSD beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		Age/Sex: >1 (Denominator: Total number of adults and	
have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		children who initiated ART in the 12 months prior to the	
lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	TX_RET_DSD	beginning of the reporting period, including those who	164
Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		have died, those who have stopped ART, and those	
children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		lost to follow-up)	
TX_RET_DSD beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		Age/Sex: 1-9 (Denominator: Total number of adults and	
have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		children who initiated ART in the 12 months prior to the	
lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	TX_RET_DSD	beginning of the reporting period, including those who	708
Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months		have died, those who have stopped ART, and those	
adults and children who initiated ART in the 12 months		lost to follow-up)	
		Age/Sex: 10-14 Male (Denominator: Total number of	
TX_RET_DSD prior to the beginning of the reporting period, including 148		adults and children who initiated ART in the 12 months	
	TX_RET_DSD	prior to the beginning of the reporting period, including	148
those who have died, those who have stopped ART,		those who have died, those who have stopped ART,	
and those lost to follow-up)		and those lost to follow-up)	
Age/Sex: 15-19 Male (Denominator: Total number of		Age/Sex: 15-19 Male (Denominator: Total number of	
adults and children who initiated ART in the 12 months		adults and children who initiated ART in the 12 months	
TX_RET_DSD prior to the beginning of the reporting period, including 108	TX_RET_DSD	prior to the beginning of the reporting period, including	108
those who have died, those who have stopped ART,		those who have died, those who have stopped ART,	
and those lost to follow-up)		and those lost to follow-up)	
TX_RET_DSD Age/Sex: 20-24 Male (Denominator: Total number of 173	TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of	173



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,973
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	653
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	165
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	498
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,561
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,262
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months	508



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	524
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,457
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	553
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,033
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	571
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,903
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	608
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,839



HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	45
HRH_PRE	By Graduates: Nurses 45	
HRH_PRE	Sum of Graduates disaggreagtes 45	

Implementing Mechanism Details

Mechanism ID: 14242	Mechanism Name: FANTA III
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 350,0	000			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 350,000				
Funding Source Funding Amount				
GHP-State	350,000			

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service	350,000
Delivery	

Badget Gode information			
Mechanism ID:	14242		
Mechanism Name:	FANTA III		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	НВНС	350,000	0

(No data provided.)

Implementing Mechanism Details

implementing incondition betains		
Mechanism ID: 14432	Mechanism Name: support to MDF	
Funding Agency: DOD Procurement Type: Contract		
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			
GHP-State	0		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Mechanism ID:	14432		
Mechanism Name:	support to MDF		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	0	0	

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans			
	Mechanism Name: Center of Excellence for		
Mechanism ID: 14441	Comprehensive Integrated HIV Care and		
	Treatment Services in Lilongwe, Malawi		
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreement			
Prime Partner Name: Lighthouse			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No Managing Agency:			

Total All Funding Sources: 4,700,0	0			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 4,700,000				
Funding Source Funding Amount				
GHP-State	4,700,000			

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	8,000
Human Resources for Health	60,000
Key Populations: FSW	10,000
Focus Area:	Implementation of core HIV prevention interventions
	for SWs consistent with PEPFAR guidance on
	sexual prevention
Renovation 50,000	



Budget Code Information

Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name: 14441 Center of Excellence for Comprehensive Integrated HIV Care and Treatment Services in Lilongwe, Malawi Lighthouse			
Strategic Area	Budget Code	Budget Code Planned Amount On Hold Amount	
Care	НВНС	773,360	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	264,920	C
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	11,520	C
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	60,000	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	199,300	C
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	93,500	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,752,720	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	544,680	(

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	2,723
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,949
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	55,672
PMTCT_STAT_DSD	Number of new ANC and L&D clients	58,601
PMTCT_STAT_DSD	By: Known positives at entry	3,223
PMTCT_STAT_DSD	By: Number of new positives identified	2,746
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	5,969
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	7
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	578
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	921
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	681
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	1,080
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	165
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	12,378
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	19,637
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	19,636



PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	6,785
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,081
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	373
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	921
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	319
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	157
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	11,758
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	18,655
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	18,655
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	6,447
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	234,256
HTC_TST_DSD	Age/sex: 10-14 Male	14,770
HTC_TST_DSD	Age/sex: 15-19 Male	12,191
HTC_TST_DSD	Age/sex: 20-24 Male	10,138
HTC_TST_DSD	Age/sex: 25-49 Male	28,932
HTC_TST_DSD	Age/sex: 50+ Male	9,279
HTC_TST_DSD	Age/sex: 10-14 Female	15,231
HTC_TST_DSD	Age/sex: 15-19 Female	12,737
HTC_TST_DSD	Age/sex: 20-24 Female	10,699
HTC_TST_DSD	Age/sex: 25-49 Female	30,905
HTC_TST_DSD	Age/sex: 50+ Female	10,680
HTC_TST_DSD	Sum of Age/Sex disaggregates	155,562
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	238
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	1,311
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male 1,09	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	3,117



HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1,000
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	246
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,371
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,151
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,330
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1,150
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	54,334
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	60,541
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	54,362
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	65,019
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	108,696
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	125,560
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	234,256
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	878
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	6,523
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	879
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	7,004
HTC_TST_DSD	Test Result by Age: Positive: <1	141
HTC_TST_DSD	Test Result by Age: Positive: 1-9	1,132
HTC_TST_DSD	Age/sex: <1	8,762
HTC_TST_DSD	Age/sex: 1-9	69,932
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	15,226
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	41,464
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0



HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	66,528
HTC_TST_DSD	Service Delivery Point (Facility): VCT	42,400
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	66,528
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,110
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,240
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,449
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	72
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,079
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	134
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,955
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,075
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,221
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	357



	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	45
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	649
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	50,710
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,150
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	16,892
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,083
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	30,585
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	507
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	37,069
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	30,325
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,397
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	3,347
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,546
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,632
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,178
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	43
PMTCT_EID_DSD	Number of infants with a positive virological test result	77



	within 12 months of birth		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	53,379	
TX_CURR_DSD	Age/Sex: 15-19 Male	375	
TX_CURR_DSD	Age/Sex: 15-19 Female	1,760	
TX_CURR_DSD	Sum of age/sex disaggregates	2,135	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,041	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	17,403	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,225	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	29,710	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,266	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	47,113	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	53,379	
TX_CURR_DSD	Age/Sex: <1	857	
TX_CURR_DSD	Age/Sex: <1-9	3,761	
TX_CURR_DSD	Age/Sex: 10-14 Male	788	
TX_CURR_DSD	Age/Sex: 10-14 Female 8		
TX_CURR_DSD	Age/Sex: 20-24 Male	626	
TX_CURR_DSD	Age/Sex: 25-49 Male	12,449	
TX_CURR_DSD	Age/Sex: 50+ Male	2,317	
TX_CURR_DSD	Age/Sex: 20-24 Female	5,533	
TX_CURR_DSD	Age/Sex: 25-49 Female	22,271	
TX_CURR_DSD	Age/Sex: 50+ Female	1,779	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,644	
TX_NEW_DSD	By Age/Sex: <1		
TX_NEW_DSD	By Age/Sex: 1-9	976	
TX_NEW_DSD	By Age/Sex: 10-14 Male 205		
TX_NEW_DSD	By Age/Sex: 15-19 Male	76	
TX_NEW_DSD	By Age/Sex: 20-24 Male 128		
TX_NEW_DSD	By Age/Sex: 25-49 Male 2,89		
TX_NEW_DSD	By Age/Sex: 50+ Male	476	



TX_NEW_DSD	By Age/Sex: 10-14 Female	224	
TX_NEW_DSD	By Age/Sex: 15-19 Female	362	
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,136	
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,578	
TX_NEW_DSD	By Age/Sex: 50+ Female	366	
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,445	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	789	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,575	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	838	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,442	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,644	
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	16,815	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	18,684	
TX_PVLS_DSD	Numerator: Indication: Routine	15,133	
TX_PVLS_DSD	Numerator: Indication: Targeted	11	
TX_PVLS_DSD	Denominator: Indication: Routine	16,815	
TX_PVLS_DSD	Denominator: Indication: Targeted	11	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	733	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	5,462	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	779	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	9,841	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	818	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	6,068	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	865	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	10,933	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,884	
TX_RET_DSD	Total number of adults and children who initiated ART	13,059	



		1	
	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have		
	stopped ART, and those lost to follow-up		
	Age/Sex: <1 (Numerator: Number of adults and children		
TX_RET_DSD	who are still alive and on treatment at 12 months after	129	
	initiating ART		
	Age/Sex: 1-9 (Numerator: Number of adults and		
TX_RET_DSD	children who are still alive and on treatment at 12	565	
	months after initiating ART		
	Age/Sex: 10-14 Male (Numerator: Number of adults		
TX_RET_DSD	and children who are still alive and on treatment at 12	117	
	months after initiating ART		
TV DET DOD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	00	
TX_RET_DSD	months after initiating ART	83	
	Age/Sed: 20-24 Male (Numerator: Number of adults		
TX RET DSD	and children who are still alive and on treatment at 12	140	
17_1121_565	months after initiating ART		
	Age/Sex: 25-49 Male (Numerator: Number of adults		
TX_RET_DSD	and children who are still alive and on treatment at 12	3,163	
	months after initiating ART		
	Age/Sex: 50+ Male (Numerator: Number of adults and		
TX_RET_DSD	children who are still alive and on treatment at 12	520	
	months after initiating ART		
	Age/Sex: 10-14 Female (Numerator: Number of adults		
TX_RET_DSD	and children who are still alive and on treatment at 12	129	
	months after initiating ART		
TV DET 505	Age/Sex: 15-19 Female (Numerator: Number of adults	005	
TX_RET_DSD	and children who are still alive and on treatment at 12 months after initiating ART	395	
	Age/Sex: 20-24 Female (Numerator: Number of adults		
TX_RET_DSD	and children who are still alive and on treatment at 12	1,243	
	months after initiating ART	1,270	
	Age/Sex: 25-49 Female (Numerator: Number of adults		
TX_RET_DSD	and children who are still alive and on treatment at 12	5,001	



	months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	399
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	620
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	129
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	155
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,476
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of	573



	T	
	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	432
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,368
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,490
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	438
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	457
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,908



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	482
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,037
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	502
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,293
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	531
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,733

Implementing Mechanism Details

<u></u>		
Mechanism ID: 14442	Mechanism Name: Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System	
	Technologies in Malawi under PEPFAR	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: BAOBAB Health Partnership		
Agreement Start Date: Redacted Agreement End Date: Redacted		



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,750,000			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 2,750,000			
Funding Source Funding Amount			
GHP-State	2,750,000		

Cross-Cutting Budget Attribution(s)

(No data provided.)

Baager Godo IIIIGIII	Budget Gode Information		
Mechanism ID: Improving Quality of Care and Health Impact through Sustainable,			
	anism Name: Integrated, Innovative Information System Technologies in Malawi under		
Prime Partner Name	PEPFAR		
	BAOBAB Health Partne	rship	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	621,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	77,570	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	83,820	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	25,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	61,830	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,574,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	305,630	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 15888	Mechanism Name: Strengthening the National OVC Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,200,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,200,000		
Funding Source Funding Amount		
GHP-USAID	1,200,000	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	15888		
Mechanism Name:	Strengthening the National OVC Program		
Prime Partner Name:	UNICEF		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16486	Mechanism Name: ASPIRE	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Save The Children Federation Inc		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	
GHP-USAID	О	

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

-uugut oous misimi			
Mechanism ID:	16486		
Mechanism Name:	ASPIRE		
Prime Partner Name:	Save The Children Fede	eration Inc	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,879
OVC_SERV_DSD	Age/Sex: 18+ Male	3,576
OVC_SERV_DSD	Age/Sex: 18+ Female	3,965
OVC_SERV_DSD	Sum of Age/Sex disaggregates	7,541
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	190
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	174
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	558
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	2,243
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	143
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	427
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	3



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	11
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	335
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	1,293
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	28
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	108
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	270
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	3,525
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	887
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	66
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	118
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,031
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,308
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	3,818
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	1,261



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	322
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	84

implementing mechanism betans			
Mechanism ID: 16678	Mechanism Name: District Health System Strengthening and Quality Improvement for		
	Service Delivery in Malawi under PEPFAR		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Management Sciences for Health			
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Total All Funding Sources: 5,752,376		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 5,752,376		
Funding Source Funding Amount		
GHP-State	5,752,376	

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Renovation	150,000

Budget Code Information

Mechanism ID: 16678



Mechanism Name: District Health System Strengthening and Quality Improvement for Prime Partner Name: Service Delivery in Malawi under PEPFAR Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	296,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	617,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	379,560	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	56,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	394,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,000,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,448,366	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	509,700	0



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	82,315
PMTCT_ART_DSD	New on ART	6,045
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7,203
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	82,315
PMTCT_STAT_DSD	Number of new ANC and L&D clients	88,179
PMTCT_STAT_DSD	By: Known positives at entry	7,647
PMTCT_STAT_DSD	By: Number of new positives identified	6,508
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	14,155
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	6
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	1,375
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	2,177
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	1,614
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	2,563
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	251
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	18,622
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	29,545
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	29,550



PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	10,211
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	2,576
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	884
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	2,199
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	751
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	236
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	17,387
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	27,586
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	27,580
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	9,527
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	610,468
HTC_TST_DSD	Age/sex: 10-14 Male	38,491
HTC_TST_DSD	Age/sex: 15-19 Male	31,773
HTC_TST_DSD	Age/sex: 20-24 Male	26,423
HTC_TST_DSD	Age/sex: 25-49 Male	75,398
HTC_TST_DSD	Age/sex: 50+ Male	24,180
HTC_TST_DSD	Age/sex: 10-14 Female	39,692
HTC_TST_DSD	Age/sex: 15-19 Female	33,194
HTC_TST_DSD	Age/sex: 20-24 Female	27,886
HTC_TST_DSD	Age/sex: 25-49 Female	80,525
HTC_TST_DSD	Age/sex: 50+ Female	27,832
HTC_TST_DSD	Sum of Age/Sex disaggregates	405,394
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	620
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	4,399
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	3,654
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	10,431



HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	3,344
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	642
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	4,596
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	3,858
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	11,143
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	3,850
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	141,591
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	157,772
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	141,668
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	169,436
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	283,259
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	327,208
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	610,467
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2,289
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	21,832
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,292
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	23,449
HTC_TST_DSD	Test Result by Age: Positive: <1	366
HTC_TST_DSD	Test Result by Age: Positive: 1-9	2,945
HTC_TST_DSD	Age/sex: <1	22,833
HTC_TST_DSD	Age/sex: 1-9	182,240
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	39,682
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	108,054
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0



	·	
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	173,374
HTC_TST_DSD	Service Delivery Point (Facility): VCT	110,493
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	173,374
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	5,491
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,535
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6,423
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	124
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,845
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	224
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,342
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,165
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,442
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	64
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	986



	<u> </u>	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	118
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,996
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	159,389
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3,619
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	53,104
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6,547
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	96,119
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,596
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	116,515
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	95,317
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	10,675
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	10,522
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,526
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	6,567
PMTCT_EID_DSD	Sum of Infant Age disaggregates	10,093
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	95
PMTCT_EID_DSD	Number of infants with a positive virological test result	177



	within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	167,782
TX_CURR_DSD	Age/Sex: 15-19 Male	1,183
TX_CURR_DSD	Age/Sex: 15-19 Female	5,534
TX_CURR_DSD	Sum of age/sex disaggregates	6,717
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	8,406
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	54,697
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	8,914
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	95,764
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	17,320
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	150,461
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	167,781
TX_CURR_DSD	Age/Sex: <1	2,370
TX_CURR_DSD	Age/Sex: <1-9	10,383
TX_CURR_DSD	Age/Sex: 10-14 Male	2,178
TX_CURR_DSD	Age/Sex: 10-14 Female	2,383
TX_CURR_DSD	Age/Sex: 20-24 Male	1,960
TX_CURR_DSD	Age/Sex: 25-49 Male	41,520
TX_CURR_DSD	Age/Sex: 50+ Male	7,283
TX_CURR_DSD	Age/Sex: 20-24 Female	17,395
TX_CURR_DSD	Age/Sex: 25-49 Female	70,001
TX_CURR_DSD	Age/Sex: 50+ Female	5,592
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	36,277
TX_NEW_DSD	By Age/Sex: <1	527
TX_NEW_DSD	By Age/Sex: 1-9	2,335
TX_NEW_DSD	By Age/Sex: 10-14 Male	485
TX_NEW_DSD	By Age/Sex: 15-19 Male	249
TX_NEW_DSD	By Age/Sex: 20-24 Male	420
TX_NEW_DSD	By Age/Sex: 25-49 Male	9,356
TX_NEW_DSD	By Age/Sex: 50+ Male	1,544



0-14 Female 530 5-19 Female 1,163 0-24 Female 3,675 5-49 Female 14,813 50+ Female 1,180	
0-24 Female 3,675 5-49 Female 14,813	
5-49 Female 14,813	
50+ Female 1,180	
,	
disaggregates 33,415	
by Age/Sex: <15 Male 1,888	
by Age/Sex: 15+ Male 11,558	
Age/Sex: <15 Female 2,006	
/ Age/Sex: 15+ Female 20,825	
ge/Sex disaggregates 36,277	
sults (<1,000 copies/ml) records and /or supporting 52,851	
the patient medical record 58,720	
cation: Routine 47,563	
ation: Targeted 27	
lication: Routine 52,851	
cation: Targeted 31	
d Age/Sex: <15 Male 2,309	
d Age/Sex: 15+ Male 17,169	
Age/Sex: <15 Female 2,452	
Age/Sex: 15+ Female 30,921	
ed Age/Sex: <15 Male 2,566	
ed Age/Sex: 15+ Male 19,078	
d Age/Sex: <15 Female 2,722	
d Age/Sex: 15+ Female 34,353	
30.786	
children who initiated ART 34,180	
	disaggregates 33,415 29 Age/Sex: <15 Male 1,888 20 Age/Sex: 15+ Male 11,558 2 Age/Sex: 15+ Female 2,006 2 Age/Sex: 15+ Female 20,825 36,277 3



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	
	stopped ART, and those lost to follow-up	
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	332
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,458
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	306
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	215
TX_RET_DSD	Age/Sed: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	367
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,191
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,351
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	335
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,021
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,221
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12	12,954



	months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,034
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	376
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,625
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	340
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	245
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	404
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,090
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of	1,494



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	378
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,139
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,575
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,366
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,150
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,179
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,054



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,248
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,305
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,307
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,384
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,321
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	35
HRH_PRE	By Graduates: Nurses	35
HRH_PRE	Sum of Graduates disaggreagtes	35

Mechanism ID: 16704	Mechanism Name: One Community (One C)



Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Johns Hopkins University Center for Communication Programs		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 4,800,0	0
Applied Pipeline Amount: 0	
Total All Funding Sources and App	ied Pipeline Amount: 4,800,000
Funding Source	Funding Amount
GHP-State	4,800,000

Economic Strengthening	900,000	
Gender: GBV	1,250,000	
Focus Area:	GBV Prevention	
Sub Area:	Collection and Use of Gender-related Strategic Information	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	
Sub Area:	Operation Research	
Gender: Gender Equality	950,000	
Focus Area:	Changing harmful gender norms and promoting positive gender norms	
Sub Area:	Implementation	
Sub Area:	Capacity building	
Education	650,000	
Condom programming	850,000	



Budget Code Information

Budget Code Information			
Mechanism ID: 16704			
Mechanism Name:	ame: One Community (One C)		
Prime Partner Name:	Johns Hopkins University Center for Communication Programs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	816,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,248,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	192,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	384,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	384,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	144,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,248,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	384,000	0

Indicator Number	Label	2017
Custom	Page 122 of 209	EACTS Info v2 9 21 10



	-	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	233,176
	minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	3,033,946
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	111,375
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	121,801
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	57,331
HTC_TST_DSD	Age/sex: 10-14 Male	3,615
HTC_TST_DSD	Age/sex: 15-19 Male	2,985
HTC_TST_DSD	Age/sex: 20-24 Male	2,481
HTC_TST_DSD	Age/sex: 25-49 Male	7,079
HTC_TST_DSD	Age/sex: 50+ Male	2,271
HTC_TST_DSD	Age/sex: 10-14 Female	3,727
HTC_TST_DSD	Age/sex: 15-19 Female	3,118
HTC_TST_DSD	Age/sex: 20-24 Female	2,619
HTC_TST_DSD	Age/sex: 25-49 Female	7,563
HTC_TST_DSD	Age/sex: 50+ Female	2,614
HTC_TST_DSD	Sum of Age/Sex disaggregates	38,072
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	288
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	245
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	203
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	583
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	187
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	297
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	257
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	215
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	622
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	215



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,818
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,304
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,912
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	26,601
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	30,730
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	57,331
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	772
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,218
HTC_TST_DSD	HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,309
HTC_TST_DSD		
HTC_TST_DSD	Test Result by Age: Positive: 1-9	855
HTC_TST_DSD	Age/sex: <1	2,145
HTC_TST_DSD	Age/sex: 1-9	17,115
HTC_TST_DSD	OSD Service Delivery Point (Community): Index testing	
HTC_TST_DSD Service Delivery Point (Community): Homebased testing		5,734
HTC_TST_DSD		
HTC_TST_DSD	Service Delivery Point (Community): Other	20,064
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	95,260
OVC_SERV_DSD	Age/Sex: 18+ Male	22,064
OVC_SERV_DSD	_DSD Age/Sex: 18+ Female	



OVC_SERV_DSD	Sum of Age/Sex disaggregates	45,234
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17 OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		0
		0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		1,137
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0



	<u> </u>	
	and sex: Parenting/Caregiver Programs Male 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14 Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17 Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24 OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24 Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+ Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		0
		0
		0
		0
		0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		3
OVC_SERV_DSD Required only for DREAMS countries - By service, age		3,350



	1	
	and sex: Economic Strengthening Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	13,458
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	856
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	2,562
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Female <1 OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14		15
		66
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	20
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24		2,012
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	7,752
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Male <1 OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14 OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17		9
		168
		45
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	653
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Male 25+		1,618
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	21,144



OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9		5,319
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	392
OVC_SERV_DSD Required only for DREAMS countries - By se and sex: Other Services Male 1-9		707
OVC_SERV_DSD By Aggregated Age/Sex: <18 Male		24,619
OVC_SERV_DSD	C_SERV_DSD By Aggregated Age/Sex: <18 Female	
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9		28,461
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	7,565
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	1,930
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9		505

Mechanism ID: 16716	Mechanism Name: STEPS	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Counterpart International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 832,110	
Applied Pipeline Amount: 200,000	
Total All Funding Sources and Applied Pipeline	Amount: 1,032,110
Funding Source	Funding Amount



GHP-State	832,110
-----------	---------

(No data provided.)

Budget Code Information

Budget Code Information				
Mechanism ID:	Mechanism ID: 16716			
Mechanism Name:	STEPS			
Prime Partner Name:	Counterpart Internation	Counterpart International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	150,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	50,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	250,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	282,110	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	100,000	0	

Implementing Mechanism Indicator Information

(No data provided.)



Mechanism ID: 16794	Mechanism Name: MCHIP/SANKHANI	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

(No data provided.)

Budget Code Information

_	Baagot Godo iiii oi iii			
	Mechanism ID:	16794		
ı	Mechanism Name:	MCHIP/SANKHANI		
	Prime Partner Name:	JHPIEGO		
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Prevention	CIRC	0	0

Indicator Number	Label	2017
VMMC CIDC DCD	Number of males circumcised as part of the voluntary	27.254
VMMC_CIRC_DSD	medical male circumcision (VMMC) for HIV prevention	27,354



	1	
	program within the reporting period	
VMMC_CIRC_DSD	By Age: 10-14	6,839
VMMC_CIRC_DSD	By Age: 15-19	10,942
VMMC_CIRC_DSD	By Age: 20-24	5,473
VMMC_CIRC_DSD	By Age: 25-29	2,736
VMMC_CIRC_DSD	By Age: 30-49	821
VMMC_CIRC_DSD	By Age: 50+	543
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	23,797
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	27,354
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	33,059
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,130
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,046
HTC_TST_DSD	Age/sex: 10-14 Male	3,424
HTC_TST_DSD	Age/sex: 15-19 Male	2,034
HTC_TST_DSD	Age/sex: 20-24 Male	811
HTC_TST_DSD	Age/sex: 25-49 Male	761
HTC_TST_DSD	Age/sex: 50+ Male	16
HTC_TST_DSD	Sum of Age/Sex disaggregates	7,046
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	282
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	168
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	66
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	63
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,423
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,623
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,423
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,623
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	7,046



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	282
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	298
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	7,046

Mechanism ID: 17097	Mechanism Name: DOD Support to Malawi Defense Force HIV AIDS Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,580,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,580,000		
Funding Source	Funding Amount	
GHP-State	1,580,000	

Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	10,000



Budget Code Information			
Mechanism ID:	17097		
Mechanism Name: DOD Support to Malawi Defense Force HIV AIDS Program			
Prime Partner Name:	Project Concern International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	160,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	85,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	120,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	690,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	617
PMTCT_ART_DSD	New on ART	60
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	617
PMTCT_STAT_DSD	Number of new ANC and L&D clients	687
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	By: Number of new positives identified	62
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	62
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	31,898
PP_PREV_DSD	Total number of people in the target population	89,963
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,964
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	15,163
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,706
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	13,065
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,685
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	728



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,246
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,387
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,324
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,115
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	15,570
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	17,685
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	94
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	765
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	106
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	661
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	1,130
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	683
HTC_TST_DSD	Service Delivery Point (Facility): VCT	15,056
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	617
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	199
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,973
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	297
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,980
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	335



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,361
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	59
PMTCT_EID_DSD	Sum of Infant Age disaggregates	59
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,340
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	312
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,137
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	352
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,538
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	664
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,675
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,339
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,524
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	87
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	629
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	98
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	710
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,524
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,219
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,339
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	69



	adults and children who are still alive and on treatment	
	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	503
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	568
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	87
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	629
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	98
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	710

Mechanism ID: 17268	Mechanism Name: Global HIV/AIDS Nursing Initiative
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement



Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0		
Applied Pipeline Amount: 0		
Total All Funding Sources and	pplied Pipeline Amount: 0	
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

Budget Code Information

Budget Gode Illioning	ation		
Mechanism ID:	17268		
Mechanism Name:	Global HIV/AIDS Nursing Initiative		
Prime Partner Name:	Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17341	Mechanism Name: Strengthening High Quality	
Wechanish ib. 17341	Laboratory Services Scale-Up for HIV Diagnosis,	



	Care, Treatment and Monitoring in Malawi under the President"s Emergency Plan for AIDS Relief (PEPFAR)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 4,200,00)	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 4,200,000		
Funding Source Funding Amount		
GHP-State	4,200,000	

Human Resources for Health	250,000
Renovation	750,000

Budget Code Information

	17341		
Mechanism ID:	Strengthening High Quality Laboratory Services Scale-Up for HIV		
Mechanism Name:	Mechanism Name: Diagnosis, Care, Treatment and Monitoring in Malawi under the		
Prime Partner Name: President"s Emergency Plan for AIDS Relief (PEPFAR)			
	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	254,090	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	950,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	906,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,639,910	0

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	57
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	57
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	57
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	57
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	57
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	57
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	9
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that	9



	<u> </u>	
	achieve acceptable successful passing criteria in this PT program	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	9
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	57
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	57
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	57
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	44
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	44
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	44
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2

	Mechanism Name: Human Resources for Health
Mechanism ID: 17451	(HRH) Capacity Building in Malawi under the
	President's Emergency Plan for AIDS Relief



	(PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Universtiy of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,900,000		
Applied Pipeline Amount: 0	•	
Total All Funding Sources and Applied Pipeline Amount: 4,900,000		
Funding Source	Funding Amount	
GHP-State	4,900,000	

Human Resources for Health	340,000
Motor Vehicles: Purchased	55,000

Budget Code Information

Mechanism ID:	Human Resources for Health (HRH) Capacity Building in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	463,150	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	390,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	405,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,262,350	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	379,500	0

(No data provided.)

Implementing Mechanism Details

mpromorting moontainem potane		
Mechanism ID: 17480	Mechanism Name: HP+	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Futures Group		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 300,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 300,000		
Funding Source	Funding Amount	
GHP-USAID	300,000	

Cross-Cutting Budget Attribution(s)

	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Condom programming	300,000
Gender: Gender Equality	300,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	75,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	75,000
Focus Area:	Monitoring and evaluation of MSM/TG programs

Budget Code Information

<u>=get e e</u>			
Mechanism ID:	17480		
Mechanism Name:	HP+		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17487	Mechanism Name: Strengthening Malawi"s Vital Statistics Systems through Civil Registration under PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Registration Bureau M	⁄lalawi
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC



Total All Funding Sources: 400,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 400,000		
Funding Source Funding Amount		
GHP-State	400,000	

(No data provided.)

Budget Code Information

Baaget Gode Information			
Mechanism ID: Mechanism Name: Prime Partner Name:	17487 Strengthening Malawi"s Vital Statistics Systems through Civil Registration under PEPFAR		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17488	Mechanism Name: Improving Medical Education in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Malawi College of Medicine	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,000,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,000,000		
Funding Source Funding Amount		
GHP-State	1,000,000	

Ì		
	Human Resources for Health	856,421

Mechanism ID: Mechanism Name:	17488 Improving Medical Education in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	18,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	13,230	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	65,790	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	444,520	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	6,380	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	12,890	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	418,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	20,260	0

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	204
PMTCT_ART_DSD	New on ART	16
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	17
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	204
PMTCT_STAT_DSD	Number of new ANC and L&D clients	215
PMTCT_STAT_DSD	By: Known positives at entry	19
PMTCT_STAT_DSD	By: Number of new positives identified	16
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	35
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	3



	· · · · · · · · · · · · · · · · · · ·	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	5
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	6
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	45
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	72
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	72
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	25
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	7
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	6
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	2
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	1
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	43
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	68
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	69
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	24
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,557



	•		
HTC_TST_DSD	Age/sex: 10-14 Male	1,233	
HTC_TST_DSD	Age/sex: 15-19 Male	1,018	
HTC_TST_DSD	Age/sex: 20-24 Male	846	
HTC_TST_DSD	Age/sex: 25-49 Male	2,415	
HTC_TST_DSD	Age/sex: 50+ Male	775	
HTC_TST_DSD	Age/sex: 10-14 Female	1,272	
HTC_TST_DSD	Age/sex: 15-19 Female	1,063	
HTC_TST_DSD	Age/sex: 20-24 Female	893	
HTC_TST_DSD	Age/sex: 25-49 Female	2,580	
HTC_TST_DSD	Age/sex: 50+ Female	892	
HTC_TST_DSD	Sum of Age/Sex disaggregates	12,987	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	20	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	220	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	183	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	522	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	167	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	21	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	230	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	193	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	558	
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	193	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,536	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,054	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,538	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,428	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,074	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,482	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,556	



·		
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	73
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,092
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	73
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,173
HTC_TST_DSD	Test Result by Age: Positive: <1	12
HTC_TST_DSD	Test Result by Age: Positive: 1-9	94
HTC_TST_DSD	Age/sex: <1	731
HTC_TST_DSD	Age/sex: 1-9	5,838
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,271
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	3,462
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	5,554
HTC_TST_DSD	Service Delivery Point (Facility): VCT	3,540
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	5,554
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	176
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	932
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	995
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	311
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	38



	of registered new and relapsed TB cases with	
	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	562
	documented HIV status, during the reporting period)	
TD ADT DOD	The number of registered new and relapse TB cases	F.47
TB_ART_DSD	with documented HIV-positive status who are on ART during TB treatment during the reporting period	547
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status during TB	601
	treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	182
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	330
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,989
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	113
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,662
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	205
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,009
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	50



TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,647	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only		
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	334	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	329	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	11	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	18	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	29	
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0	
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	1	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,252	
TX_CURR_DSD	Age/Sex: 15-19 Male	37	
TX_CURR_DSD	Age/Sex: 15-19 Female	173	
TX_CURR_DSD	Sum of age/sex disaggregates	210	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	266	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,712	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	282	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,991	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	548	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,703	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,251	
TX_CURR_DSD	Age/Sex: <1	75	
TX_CURR_DSD	Age/Sex: <1-9	329	
TX_CURR_DSD	Age/Sex: 10-14 Male	69	
TX_CURR_DSD	Age/Sex: 10-14 Female	76	



TX_CURR_DSD	Age/Sex: 20-24 Male	62	
TX_CURR_DSD	Age/Sex: 25-49 Male	1,293	
TX_CURR_DSD	Age/Sex: 50+ Male	228	
TX_CURR_DSD	Age/Sex: 20-24 Female	544	
TX_CURR_DSD	Age/Sex: 25-49 Female	2,191	
TX_CURR_DSD	Age/Sex: 50+ Female	175	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,601	
TX_NEW_DSD	By Age/Sex: <1	15	
TX_NEW_DSD	By Age/Sex: 1-9	67	
TX_NEW_DSD	By Age/Sex: 10-14 Male	14	
TX_NEW_DSD	By Age/Sex: 15-19 Male	12	
TX_NEW_DSD	By Age/Sex: 20-24 Male	19	
TX_NEW_DSD	By Age/Sex: 25-49 Male	430	
TX_NEW_DSD	By Age/Sex: 50+ Male	71	
TX_NEW_DSD	By Age/Sex: 10-14 Female	15	
TX_NEW_DSD	By Age/Sex: 15-19 Female	54	
TX_NEW_DSD	By Age/Sex: 20-24 Female	169	
TX_NEW_DSD	By Age/Sex: 25-49 Female	681	
TX_NEW_DSD	By Age/Sex: 50+ Female	54	
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,519	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	54	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	532	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	57	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	958	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,601	
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,654	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,838	



	•		
TX_PVLS_DSD	Numerator: Indication: Routine	1,489	
TX_PVLS_DSD	Numerator: Indication: Targeted	1	
TX_PVLS_DSD	Denominator: Indication: Routine	1,654	
TX_PVLS_DSD	Denominator: Indication: Targeted	1	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	72	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	537	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	77	
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	968	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	80	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	597	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	85	
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,075	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	511	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	561	
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6	
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	24	
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4	
TX_RET_DSD	Age/Sed: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6	
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults	136	



	,	
	and children who are still alive and on treatment at 12	
	months after initiating ART	
	Age/Sex: 50+ Male (Numerator: Number of adults and	
TX_RET_DSD	children who are still alive and on treatment at 12	22
	months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	6
	months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	17
	months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	53
	months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	214
	months after initiating ART	
	Age/Sex: 50+ Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	17
	months after initiating ART	
	Age/Sex: >1 (Denominator: Total number of adults and	
	children who initiated ART in the 12 months prior to the	
TX_RET_DSD	beginning of the reporting period, including those who	6
	have died, those who have stopped ART, and those	
	lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and	
	children who initiated ART in the 12 months prior to the	
TX_RET_DSD	beginning of the reporting period, including those who	27
	have died, those who have stopped ART, and those	
	lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of	
	adults and children who initiated ART in the 12 months	
TX_RET_DSD	prior to the beginning of the reporting period, including	6
	those who have died, those who have stopped ART,	
	and those lost to follow-up)	



TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	149
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of	236



	· · · · · · · · · · · · · · · · · · ·	
	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	168
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	302
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	185
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	23



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	332
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	4
HRH_PRE	By Graduates: Doctors	4
HRH_PRE	Sum of Graduates disaggreagtes	4

Mechanism ID: 17585	Mechanism Name: Linkages
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,773,759		
Applied Pipeline Amount: 466,241		
Total All Funding Sources and Applied Pipeline A	amount: 2,240,000	
Funding Source Funding Amount		
GHP-State	1,773,759	

Cross-Cutting Budget Attribution(s)

	\-\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Key Populations: MSM and TG	112,000
Focus Area:	Training of health workers and community outreach
	workers
Key Populations: FSW	112,000
Focus Area:	Collection and use of strategic information on SWs



	and clients
Gender: GBV	672,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Condom programming	784,000
Motor Vehicles: Leased	600
Motor Vehicles: Purchased	40,000
Human Resources for Health	425,000

Budget Code Information

Budget Code Inform	ation		
Mechanism ID:	17585		
Mechanism Name:	Mechanism Name: Linkages		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	410,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	328,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	303,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	22,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	709,359	0



Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	10,141
KP_PREV_DSD	Total estimated number of key population in the catchment area	44,131
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,245
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,049
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,847
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area	5,441
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	13,322
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	25,368
HTC_TST_DSD	Number of individuals who received T&C services for	13,879



	HIV and received their test results during the past 12	
HTC_TST_DSD	months Age/sex: 15-19 Male	778
HTC_TST_DSD	Age/sex: 20-24 Male	647
HTC_TST_DSD	Age/sex: 25-49 Male	1,847
HTC_TST_DSD	Age/sex: 50+ Male	592
HTC_TST_DSD	Age/sex: 15-19 Female	1,963
HTC_TST_DSD	Age/sex: 20-24 Female	1,648
HTC_TST_DSD	Age/sex: 25-49 Female	4,760
	, and the second	· ·
HTC_TST_DSD	Age/sex: 50+ Female	1,645
HTC_TST_DSD	Sum of Age/Sex disaggregates	13,880
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	135
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	113
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	320
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	103
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,229
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,034
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,983
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1,031
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,864
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,014
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	13,878
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	13,878
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	668
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,279
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	2,776
HTC_TST_DSD	Service Delivery Point (Community): Other	11,103
GEND_GBV_DSD	Number of people receiving post-GBV care	2,175



GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	134
GEND_GBV_DSD	Age/Sex: 25-49 Male	106
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	0
GEND_GBV_DSD	Age/Sex: 10-14 Female	0
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,022
GEND_GBV_DSD	Age/Sex: 25-49 Female	673
GEND_GBV_DSD	Age/Sex: 50+ Female	0
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	0
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,175
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0
GEND_GBV_DSD	Age/Sex: 15-19 Female	202
GEND_GBV_DSD	Age/Sex: 15-19 male	43

Mechanism ID: 17590	Mechanism Name: Project SOAR	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: Population Council		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline	Amount: 400,000
Funding Source Funding Amount	
GHP-State	400,000



(No data provided.)

Budget Code Information

Budget Code Illionia	ation		
Mechanism ID:	17590		
Mechanism Name:	Project SOAR		
Prime Partner Name:	Population Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17594	Mechanism Name: SIFPO	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source Funding Amount	
GHP-State	0



(No data provided.)

Budget Code Informa	ation		
Mechanism ID:	17594		
Mechanism Name:	SIFPO	SIFPO	
Prime Partner Name:	Population Services Int	ernational	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	18,255
PP_PREV_DSD	Total number of people in the target population	2,952,561
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	8,755
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	9,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	99,846



	months	
HTC_TST_DSD	Age/sex: 10-14 Male	3,354
HTC_TST_DSD	Age/sex: 15-19 Male	1,993
HTC_TST_DSD	Age/sex: 20-24 Male	15,869
HTC_TST_DSD	Age/sex: 25-49 Male	43,765
HTC_TST_DSD	Age/sex: 50+ Male	15
HTC_TST_DSD	Age/sex: 15-19 Female	18,942
HTC_TST_DSD	Age/sex: 20-24 Female	15,910
HTC_TST_DSD	Sum of Age/Sex disaggregates	99,848
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,157
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	168
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,617
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,287
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	61
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,354
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	61,644
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	34,848
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,354
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	96,492
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	99,846
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	168
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,449
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,674
HTC_TST_DSD	Service Delivery Point (Community): Index testing	4,647
HTC_TST_DSD	Service Delivery Point (Community): Homebased	9,295



	testing	
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	46,473
HTC_TST_DSD	Service Delivery Point (Community): Other	32,530
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	6,904
GEND_GBV_DSD	Number of people receiving post-GBV care	2,398
GEND_GBV_DSD	Age/Sex: 10-14 Female	726
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,199
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	726
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,398
GEND_GBV_DSD	Age/Sex: 15-19 Female	473

Mechanism ID: 17720	Mechanism Name: Military Electronic Health Information Network
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: VISTA PARTNERS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID: Mechanism Name: Prime Partner Name:	Military Electronic Health Information Network		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

(No data provided.)

Implementing Mechanism Details

implementing incomanion because		
Mechanism ID: 18005	Mechanism Name: Challenge TB	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: KNCV Tuberculosis Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 350,000	
Applied Pipeline Amount: 1,595,347	
Total All Funding Sources and Applied Pipeline Amount: 1,945,347	
Funding Source Funding Amount	
GHP-USAID	350,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID:	18005		
Mechanism Name:	Challenge TB		
Prime Partner Name:	KNCV Tuberculosis Fou	undation	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	350,000	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18024	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18025	TBD: Yes
REDACTED	

Mechanism ID: 18028	Mechanism Name: Malawi Scholarship Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 847,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 847,000
Funding Source	Funding Amount



GHP-USAID	847,000

Human Resources for Health	847,000

Budget Code Information

Baagot oodo iiiioiiii	u		
Mechanism ID:	18028		
Mechanism Name:	Malawi Scholarship Program		
Prime Partner Name:	World Learning		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	847,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
	Number of new HCW who graduated from a pre-service training institution or program as a result of	
HRH_PRE	PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	50
HRH_PRE	By Graduates: Other	50
HRH_PRE	Sum of Graduates disaggreagtes	50

Mechanism ID: 18045	Mechanism Name: Bringing VMMC Services to Scale in the MDF
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 70,000 Applied Pipeline Amount: 355,000		
Total All Funding Sources and Applied Pipeline Amount: 425,000		
Funding Source Funding Amount		
GHP-State	70,000	

(No data provided.)

Budget Code Information

zaaget eeue iiii eiiii			
Mechanism ID:	18045		
Mechanism Name:	Bringing VMMC Services to Scale in the MDF		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	70,000	0

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	4,709
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0



VMMC_CIRC_DSD By Age: 10-14 942 VMMC_CIRC_DSD By Age: 15-19 1,884 VMMC_CIRC_DSD By Age: 20-24 848 VMMC_CIRC_DSD By Age: 25-29 565 VMMC_CIRC_DSD By Age: 30-49 471 VMMC_CIRC_DSD By Age: 50+ 0 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 0 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 <th></th> <th></th> <th></th>			
VMMC_CIRC_DSD By Age: 20-24 848 VMMC_CIRC_DSD By Age: 25-29 565 VMMC_CIRC_DSD By Age: 30-49 471 VMMC_CIRC_DSD By Age: 50+ 0 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD Age/sex: 10-14 M	VMMC_CIRC_DSD	By Age: 10-14	942
VMMC_CIRC_DSD By Age: 25-29 565 VMMC_CIRC_DSD By Age: 30-49 471 VMMC_CIRC_DSD By Age: 50+ 0 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 Number of individuals who received T&C services for HIV and received their test results during the past 12 months 4,709 HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 <td>VMMC_CIRC_DSD</td> <td>By Age: 15-19</td> <td>1,884</td>	VMMC_CIRC_DSD	By Age: 15-19	1,884
VMMC_CIRC_DSD By Age: 30-49 471 VMMC_CIRC_DSD By Age: 50+ 0 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 Number of individuals who received T&C services for HIV and received their test results during the past 12 months 4,709 HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 50+ Female	VMMC_CIRC_DSD	By Age: 20-24	848
VMMC_CIRC_DSD By Age: 50+ 0 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,710 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 Number of individuals who received T&C services for HIV and received their test results during the past 12 months 4,709 HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 11-19 Male 1,884 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Test Result by Age	VMMC_CIRC_DSD	By Age: 25-29	565
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 3,674 VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 4,710 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 Number of individuals who received T&C services for HIV and received their test results during the past 12 months 4,709 HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result b	VMMC_CIRC_DSD	By Age: 30-49	471
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 4,710 VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 Number of individuals who received T&C services for HIV and received their test results during the past 12 months 4,709 HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 25-49 Male 0 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 <td< td=""><td>VMMC_CIRC_DSD</td><td>By Age: 50+</td><td>0</td></td<>	VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 4,709 VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 Number of individuals who received T&C services for HIV and received their test results during the past 12 months 4,709 HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Se	VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	3,674
VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 0 Number of individuals who received T&C services for HIV and received their test results during the past 12 months HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male	VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	4,710
Number of individuals who received T&C services for HIV and received their test results during the past 12 months HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0	VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	4,709
HTC_TST_DSD HIV and received their test results during the past 12 months HTC_TST_DSD Age/sex: 10-14 Male 942 HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
HTC_TST_DSD Age/sex: 15-19 Male 1,884 HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	HIV and received their test results during the past 12	4,709
HTC_TST_DSD Age/sex: 20-24 Male 848 HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	Age/sex: 10-14 Male	942
HTC_TST_DSD Age/sex: 25-49 Male 1,035 HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0	HTC_TST_DSD	Age/sex: 15-19 Male	1,884
HTC_TST_DSD Age/sex: 50+ Male 0 HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0	HTC_TST_DSD	Age/sex: 20-24 Male	848
HTC_TST_DSD Age/sex: 10-14 Female 0 HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0	HTC_TST_DSD	Age/sex: 25-49 Male	1,035
HTC_TST_DSD Age/sex: 15-19 Female 0 HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female	HTC_TST_DSD	Age/sex: 50+ Male	0
HTC_TST_DSD Age/sex: 20-24 Female 0 HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female	HTC_TST_DSD	Age/sex: 10-14 Female	0
HTC_TST_DSD Age/sex: 25-49 Female 0 HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female	HTC_TST_DSD	Age/sex: 15-19 Female	0
HTC_TST_DSD Age/sex: 50+ Female 0 HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 Test Result by Age and Sex: Positive: 15-19 Female	HTC_TST_DSD	Age/sex: 20-24 Female	0
HTC_TST_DSD Sum of Age/Sex disaggregates 4,709 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female	HTC_TST_DSD	Age/sex: 25-49 Female	0
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female	HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	Sum of Age/Sex disaggregates	4,709
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	0
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 0 HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	0
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 0	HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
	HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Female 0	HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	0
	HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	0



Test Result by Age and Sex: Positive: 25-49 Female	0
Test Result by Age and Sex: Positive: 50+ Female	0
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,000
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,709
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
Sum of Aggregated Age/Sex <15	1,000
Sum of Aggregated Age/Sex 15+	3,709
Sum of Aggregated Age/Sex disaggregates	4,709
Test Result by Aggregated Age and Sex: Positive <15 Male	0
Test Result by Aggregated Age and Sex: Positive 15+ Male	0
Test Result by Aggregated Age and Sex: Positive <15 Female	0
Test Result by Aggregated Age and Sex: Positive 15+ Female	0
Test Result by Age: Positive: <1	0
Test Result by Age: Positive: 1-9	0
Age/sex: <1	0
Age/sex: 1-9	0
Service Delivery Point (Facility): VMMC	4,709
	Test Result by Age and Sex: Positive: 50+ Female Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex <15 Sum of Aggregated Age/Sex disaggregates Test Result by Aggregated Age and Sex: Positive <15 Male Test Result by Aggregated Age and Sex: Positive 15+ Male Test Result by Aggregated Age and Sex: Positive <15 Female Test Result by Aggregated Age and Sex: Positive 15+ Female Test Result by Aggregated Age and Sex: Positive 15+ Female Test Result by Aggregated Age Positive: <1 Test Result by Age: Positive: <1 Test Result by Age: Positive: 1-9 Age/sex: <1 Age/sex: 1-9

Mechanism ID: 18063	Mechanism Name: Global Health Supply Chain Program	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Global Health Supply Chain Program		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,680,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 1,680,000
Funding Source	Funding Amount
GHP-State	350,000
GHP-USAID	1,330,000

Condom programming	150,000
Human Resources for Health	218,000
Motor Vehicles: Purchased	60,000

Budget Code information			
Mechanism ID:	: 18063		
Mechanism Name:	Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply C	hain Program	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	151,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	218,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	184,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	537,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	453,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	134,400	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18125	Mechanism Name: ASSIST	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 600,000
Funding Source	Funding Amount
GHP-State	600,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Daaget Oode Inform	ation		
Mechanism ID:	18125		
Mechanism Name:	ASSIST		
Prime Partner Name:	University Research Co	rporation, LLC	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18142	Mechanism Name: SIFPO 2	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 998,000	
Applied Pipeline Amount: 549,000	
Total All Funding Sources and Applied Pipeline A	Amount: 1,547,000
Funding Source Funding Amount	
GHP-USAID	998,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	176,000
Key Populations: MSM and TG	25,000



Focus Area:	Training of health workers and community outreach
	workers
Key Populations: FSW	250,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Condom programming	708,580
Gender: Gender Equality	350,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Human Resources for Health	30,000

Budget Code information			
Mechanism ID:	18142		
Mechanism Name:	SIFPO 2		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	29,940	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	29,940	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	708,580	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	149,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	79,840	0

Indicator Number	Label	2017
	Number of males circumcised as part of the voluntary	
VMMC_CIRC_DSD	medical male circumcision (VMMC) for HIV prevention	42,285
	program within the reporting period	
VMMC_CIRC_DSD	By Age: 10-14	10,571
VMMC_CIRC_DSD	By Age: 15-19	16,917
VMMC_CIRC_DSD	By Age: 20-24	8,462
VMMC_CIRC_DSD	By Age: 25-29	4,238
VMMC_CIRC_DSD	By Age: 30-49	1,261
VMMC_CIRC_DSD	By Age: 50+	836
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	36,786
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	42,285
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	40,888
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,397
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,408
PP_PREV_DSD	Total number of people in the target population	362,506
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	3,536
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	3,872
HTC_TST_DSD	Number of individuals who received T&C services for	34,298



	HIV and received their test results during the past 12	
	months	
HTC_TST_DSD	Age/sex: 20-24 Male	4,084
HTC_TST_DSD	Age/sex: 25-49 Male	10,209
HTC_TST_DSD	Age/sex: 15-19 Female	5,716
HTC_TST_DSD	Age/sex: 20-24 Female	14,289
HTC_TST_DSD	Sum of Age/Sex disaggregates	34,298
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	536
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,340
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	539
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,346
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,293
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,005
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	34,298
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	34,298
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,876
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,885
HTC_TST_DSD	Service Delivery Point (Community): Index testing	1,715
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	3,430
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	17,149
HTC_TST_DSD	Service Delivery Point (Community): Other	12,004
GEND_GBV_DSD	Number of people receiving post-GBV care	3,318
GEND_GBV_DSD	Age/Sex: 10-14 Female	931



GEND_GBV_DSD	Age/Sex: 20-24 Female	1,708
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	931
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,318
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0
GEND_GBV_DSD	Age/Sex: 15-19 Female	679

Mechanism ID: 18234	Mechanism Name: EQUIP	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Right To Care, South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: No	Managing Agency:	

Total All Funding Sources: 20,72	4,217	
Applied Pipeline Amount: 2,022,	543	
Total All Funding Sources and Applied Pipeline Amount: 22,746,760		
Funding Source	Funding Amount	
GHP-State	15,720,111	
GHP-USAID	5,004,106	

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Renovation	100,000
Human Resources for Health	500,000
Gender: GBV	500,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Capacity building
Motor Vehicles: Purchased	240,000

Budget Code Information

Budget Code Information			
Mechanism ID:	18234		
Mechanism Name:	EQUIP		
Prime Partner Name:	Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,249,773	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,492,546	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	980,850	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	207,712	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	204,212	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	103,857	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	623,136	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	830,849	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	10,650,176	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	3,381,106	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	256,200
PMTCT_ART_DSD	New on ART	14,333
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	15,548
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	256,200
PMTCT_STAT_DSD	Number of new ANC and L&D clients	273,977
PMTCT_STAT_DSD	By: Known positives at entry	17,148
PMTCT_STAT_DSD	By: Number of new positives identified	14,610
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	31,758
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	3,087
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	4,890
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	3,626



	known positives: <15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	19
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	5,742
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	773
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	57,873
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	91,813
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	91,791
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	31,727
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	5,768
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	1,993
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	4,936
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	1,689
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	723
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	54,112
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	85,854
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	85,848
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	29,663
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,605,998
HTC_TST_DSD	Age/sex: 10-14 Male	101,261
HTC_TST_DSD	Age/sex: 15-19 Male	83,592
HTC_TST_DSD	Age/sex: 20-24 Male	69,510



HTC_TST_DSD	Age/sex: 25-49 Male	198,346
HTC_TST_DSD	Age/sex: 50+ Male	63,610
HTC_TST_DSD	Age/sex: 10-14 Female	104,418
HTC_TST_DSD	Age/sex: 15-19 Female	87,331
HTC_TST_DSD	Age/sex: 20-24 Female	73,363
HTC_TST_DSD	Age/sex: 25-49 Female	211,855
HTC_TST_DSD	Age/sex: 50+ Female	73,225
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,066,511
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	1,637
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	9,945
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	8,269
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	23,616
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	7,575
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	1,683
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	10,397
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	8,735
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	25,231
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	8,720
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	372,497
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	415,042
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	372,684
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	445,775
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	745,181
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	860,817
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,605,998
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	6,024
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	49,423



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	6,026
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	53,067
HTC_TST_DSD	Test Result by Age: Positive: <1	968
HTC_TST_DSD	Test Result by Age: Positive: 1-9	7,742
HTC_TST_DSD	Age/sex: <1	60,069
HTC_TST_DSD	Age/sex: 1-9	479,418
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	104,391
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	284,267
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	456,104
HTC_TST_DSD	Service Delivery Point (Facility): VCT	290,682
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	456,104
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	14,450
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7,918
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	8,528
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	184
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,621
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	338
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	4,775



	documented HIV status, during the reporting period)	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,610
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,871
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	59
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	857
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	118
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,576
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	326,946
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	7,413
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	108,916
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	13,427
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	197,190
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,265
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	238,999
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear	195,512



	only	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	21,908
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	21,579
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	8,006
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	13,630
PMTCT_EID_DSD	Sum of Infant Age disaggregates	21,636
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	225
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	396
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	344,155
TX_CURR_DSD	Age/Sex: 15-19 Male	2,428
TX_CURR_DSD	Age/Sex: 15-19 Female	11,347
TX_CURR_DSD	Sum of age/sex disaggregates	13,775
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	17,929
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	112,199
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	19,019
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	195,008
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	36,948
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	307,207
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	344,155
TX_CURR_DSD	Age/Sex: <1	5,056
TX_CURR_DSD	Age/Sex: <1-9	22,154
TX_CURR_DSD	Age/Sex: 10-14 Male	4,641
TX_CURR_DSD	Age/Sex: 10-14 Female	5,087
TX_CURR_DSD	Age/Sex: 20-24 Male	4,033
TX_CURR_DSD	Age/Sex: 25-49 Male	83,741
TX_CURR_DSD	Age/Sex: 50+ Male	14,939



TX_CURR_DSD	Age/Sex: 20-24 Female	35,680
TX_CURR_DSD	Age/Sex: 25-49 Female	143,581
TX_CURR_DSD	Age/Sex: 50+ Female	11,468
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	91,441
TX_NEW_DSD	By Age/Sex: <1	1,102
TX_NEW_DSD	By Age/Sex: 1-9	4,835
TX_NEW_DSD	By Age/Sex: 10-14 Male	1,011
TX_NEW_DSD	By Age/Sex: 15-19 Male	640
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,077
TX_NEW_DSD	By Age/Sex: 25-49 Male	24,083
TX_NEW_DSD	By Age/Sex: 50+ Male	3,968
TX_NEW_DSD	By Age/Sex: 10-14 Female	1,119
TX_NEW_DSD	By Age/Sex: 15-19 Female	3,015
TX_NEW_DSD	By Age/Sex: 20-24 Female	9,453
TX_NEW_DSD	By Age/Sex: 25-49 Female	38,088
TX_NEW_DSD	By Age/Sex: 50+ Female	3,050
TX_NEW_DSD	Sum of Age/Sex disaggregates	85,504
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	3,912
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	29,761
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4,149
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	53,619
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	91,441
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	108,398
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	120,454
TX_PVLS_DSD	Numerator: Indication: Routine	97,569
TX_PVLS_DSD	Numerator: Indication: Targeted	41
TX_PVLS_DSD	Denominator: Indication: Routine	108,398



TX_PVLS_DSD	Denominator: Indication: Targeted	47
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	4,738
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	35,210
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	5,027
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	63,423
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	5,258
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	39,124
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5,581
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	70,491
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	59,393
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	65,406
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	638
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,820
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	596
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	429
TX_RET_DSD	Age/Sed: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	692
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,797
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and	2,598



	children who are still alive and on treatment at 12	
	months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	648
	months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	1,978
	months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	6,209
	months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	24,992
	months after initiating ART	
	Age/Sex: 50+ Female (Numerator: Number of adults	
TX_RET_DSD	and children who are still alive and on treatment at 12	1,996
	months after initiating ART	
	Age/Sex: >1 (Denominator: Total number of adults and	
	children who initiated ART in the 12 months prior to the	
TX_RET_DSD	beginning of the reporting period, including those who	704
	have died, those who have stopped ART, and those	
	lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and	
	children who initiated ART in the 12 months prior to the	
TX_RET_DSD	beginning of the reporting period, including those who	3,107
	have died, those who have stopped ART, and those	
	lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of	
	adults and children who initiated ART in the 12 months	
TX_RET_DSD	prior to the beginning of the reporting period, including	651
	those who have died, those who have stopped ART,	
	and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of	
TX_RET_DSD	adults and children who initiated ART in the 12 months	472
	prior to the beginning of the reporting period, including	



	those who have died, those who have stopped ART,	
	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	768
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,402
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,866
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	713
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,180
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,835
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	27,507



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,201
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,220
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,040
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,356
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35,777
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,451
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,967
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,596
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	39,392



12 months prior to the beginning of the reporting period,	
including those who have died, those who have	
stopped ART, and those lost to follow-up)	

Implementing Mechanism Details

Mechanism ID: 18244	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18245	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 18246	Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: Health Research Inc./New York State Department of Health		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: Yes		
G2G: No	Managing Agency:	

Total All Funding Sources: 400,000			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 400,000			
Funding Source Funding Amount			
GHP-State	400,000		

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18246		
Mechanism Name:	Quality Improvement Capacity for Impact Project (QICIP)		
Prime Partner Name:	Health Research Inc./New York State Department of Health		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Treatment	HTXS	400,000	O

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

implementing wechanism betalls		
Mechanism ID: 18247	Mechanism Name: Technical Assistance to Provide High-Quality Voluntary Medical Male Circumcision (VMMC) Services to Programs Supported by the President's Emergency Plan for AIDS Relief (PEPFAR)	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreeme		
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: No	Managing Agency:	

Total All Funding Sources: 500,000		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 500,000		
Funding Source Funding Amount		
GHP-State	500,000	



Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	55.000
Motor Venicles. Purchased	33,000

Budget Code Information

Budget Code information			
	18247		
Mechanism ID:	Technical Assistance to Provide High-Quality Voluntary Medical Male		
Mechanism Name:	Circumcision (VMMC) Services to Programs Supported by the		
Prime Partner Name:	President's Emergency Plan for AIDS Relief (PEPFAR)		
	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	35,000
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	8,750
VMMC_CIRC_DSD	By Age: 15-19	14,011
VMMC_CIRC_DSD	By Age: 20-24	7,012
VMMC_CIRC_DSD	By Age: 25-29	3,512
VMMC_CIRC_DSD	By Age: 30-49	1,033
VMMC_CIRC_DSD	By Age: 50+	682
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	30,455
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	35,000



VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	33,843
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,157
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,163
HTC_TST_DSD	Age/sex: 10-14 Male	4,453
HTC_TST_DSD	Age/sex: 15-19 Male	2,645
HTC_TST_DSD	Age/sex: 20-24 Male	1,055
HTC_TST_DSD	Age/sex: 25-49 Male	990
HTC_TST_DSD	Age/sex: 50+ Male	20
HTC_TST_DSD	Sum of Age/Sex disaggregates	9,163
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	366
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	218
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	87
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	81
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	2
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,452
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,711
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,452
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,711
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	9,163
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	366
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	388
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	9,163

Implementing Mechanism Details

Mechanism ID: 18256	Mechanism Name: Construction and Renovation	
Funding Agency: State/AF	Procurement Type: Contract	
Prime Partner Name: Regional Procurement Support Office/Frankfurt		



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline	Amount: 1,000,000
Funding Source	Funding Amount
GHP-State	1,000,000

Cross-Cutting Budget Attribution(s)

Construction	1,000,000
Water	95,903

Budget Code Information

Baaget Gode Information			
Mechanism ID:	18256		
Mechanism Name:	Construction and Renovation		
Prime Partner Name:	Regional Procurement Support Office/Frankfurt		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18279	Mechanism Name: Coordinating Comprehensive	
Weethanish ib. 10279	Care for Children (4Children)	!



Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Catholic Relief Services		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: No	Managing Agency:	

Total All Funding Sources: 1,709,642	
Applied Pipeline Amount: 0	askina Amazunta 4 700 C40
Total All Funding Sources and Applied Pi	Deline Amount: 1,709,642
Funding Source	Funding Amount
GHP-State	1,709,642

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Baaget Coac Informe	4.1011		
Mechanism ID:	8279		
Mechanism Name:	Coordinating Comprehensive Care for Children (4Children)		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,563,274	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	146,368	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
------------------	-------	------



OVC_SERV_DSD				
	HIV/AIDS			
OVC_SERV_DSD	Age/Sex: 18+ Male	4,078		
OVC_SERV_DSD	Age/Sex: 18+ Female	4,522		
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,600		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	215		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	0		
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0		
OVC_SERV_DSD	C_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24			



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	198
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	
OVC_SERV_DSD	OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	636
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	163
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	488
OVC_SERV_DSD	4	



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	12
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	383
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	1,474
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	33
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	124
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	308
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	4,019
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	73
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	134
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,598
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,912
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	4,354
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	1,437
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	367



OVC SERV DSD	Required only for DREAMS countries - By service, age	96
OVC_SERV_DSD	and sex: Other Services Female 1-9	30

Implementing Mechanism Details

Mechanism ID: 18303	TBD: Yes
REDA	ACTED

Implementing Mechanism Details

Mechanism ID: 18305	Mechanism Name: HRH 2030			
Funding Agency: USAID	Procurement Type: Cooperative Agreement			
Prime Partner Name: Chemonics International				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: Yes			
G2G: No	Managing Agency:			

Total All Funding Sources: 1,230,000				
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 1,230,000				
Funding Source Funding Amount				
GHP-State	1,230,000			

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18305		
Mechanism Name:	HRH 2030		
Prime Partner Name:	Chemonics Internationa	nl .	
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	680,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18351	TBD: Yes	
REDACTED		

Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing			17,000	0	17,000	17,000
Computers/IT			163,470	0	163,470	163,470

Custom Page 203 of 208 FACTS Info v3.8.21.10

2017-04-11 09:07 EDT



Total	0	0	4,520,895	550,000	4,520,895	5,070,895
Recruited						
Locally						
Benefits -			896,536	150,000	896,536	1,046,536
Salaries and						
USG Staff						
Recruited						
Internationally						
Benefits -			1,232,767	400,000	1,232,767	1,632,767
Salaries and						
USG Staff						
Renovation			30,868	0	30,868	30,868
USG			20.000	_	20.000	20.000
Travel			475,339	0	475,339	475,339
Staff Program			A7E 220	0	475,339	47E 220
Costs						
Non-ICASS Administrative			282,394	0	282,394	282,394
Development						
Meetings/Profes sional			776,008	0	776,008	776,008
Management						
ICASS			646,513	0	646,513	646,513
Services						

U.S. Department of Defense

						Total All
						Cost of
Agency Cost of Doing Business				Applied		Doing
	GAP	GHP-State	GHP-USAID		Total	Business
				Pipeline		Categories
						Pipeline



						Amount
Computers/IT Services		0		1,632	0	1,632
ICASS		0		15,389	0	15,389
Management Meetings/Profes sional Development		0		5,014	0	5,014
Non-ICASS Administrative Costs		0		3,265	0	3,265
Staff Program Travel		0		19,610	0	19,610
USG Staff Salaries and Benefits - Locally Recruited		0		100,090	0	100,090
Total	0	0	0	145,000	0	145,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing	508,340			0	508,340	508,340
Computers/IT		131,800		0	131,800	131,800



Administrative Costs		126,600		0	126,600	126,600
Staff Program	0	218,840		0	218,840	218,840
Travel USG Staff Salaries and Benefits - Internationally Recruited	0	2,387,990		0	2,387,990	2,387,990
USG Staff Salaries and Benefits - Locally Recruited	0	1,114,829		0	1,114,829	1,114,829
Total	1,512,500	4,207,500	0	0	5,720,000	5,720,000

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT		0		13,500	0	13,500



Total	0	0	0	462,695	0	462,695
Recruited						
Locally						
Benefits -		0		133,750	0	133,750
Salaries and						
USG Staff						
Recruited						
Internationally						
Benefits -		0		0	0	0
Salaries and						
USG Staff						
Travel		0		12,050	0	12,050
Staff Program				40.050		40.050
Costs						
Administrative		0		29,830	0	29,830
Non-ICASS						
Development						
sional		0		36,150	0	36,150
Management Meetings/Profes						
Institutional Contractors				50,000	0	50,000
ICASS		0		187,415	0	187,415
Services						

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline
-------------------------------------	-----	-----------	-----------	---------------------	-------	--



						Amount
Non-ICASS Administrative Costs		61,942		108,431	61,942	170,373
Peace Corps Volunteer Costs		392,521		652,111	392,521	1,044,632
Staff Program Travel		22,091		38,671	22,091	60,762
USG Staff Salaries and Benefits - Locally Recruited		63,287		110,786	63,287	174,073
Total	0	539,841	0	909,999	539,841	1,449,840